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ABSTRACT 
PFKFB3, an isoform of PFK-2, which is highly expressed in cancer cells, has been 
suggested to be associated with enhanced aerobic glycolysis in cancer by elevating the 
intracellular levels of key glycolytic activator, Fru-2,6-P2. This work describes the importance of 
PFKFB3 function in metabolic alterations and adaptations of cancers, providing new insights 
into the PFKFB3-associated ROS regulation in cancer and suggesting promising strategies for 
cancer drug development. The first study investigates the therapeutic potential of novel PFKFB3 
inhibitors as well as the molecular mechanism of PFKFB3 inhibition. I was able to identify small 
molecular inhibitors, N4A and YN1, which almost constantly inhibit PFKFB3 and ultimately 
lead to cancer cell death. I determined the crystal structure of PFKFB3 in complex with those 
inhibitors and these structures revealed the molecular mechanism of inhibitor-recognition by 
PFKFB3. Providing direct information on the interaction between a potential drug molecule and 
its target protein at the molecular level, this study established a framework for future 
development efforts and validated PFKFB3 as a target for new cancer therapies. 
The second study investigates the functional involvement of PFKFB3 in ROS regulation 
within cancer cells. We found PFKFB3 to be S-glutathionylated under excessive oxidative stress, 
which leads to inactivation of the kinase activity of PFKFB3  Consequently, the activation of 
PFKFB3, induced by S-glutathionylation, decreases cellular Fru-2,6-P2 levels and reroutes the 
glucose metabolic flux from glycolysis to the PPP, maintaining oxidative homeostasis in cancer 
cells. The ability of PFKFB3 to control ROS levels can not only support cancer cell survival but 
also maintain cell cycle progression. This study provides a new insight into the roles of PFKFB3 
as a master switch that senses and controls redox homeostasis in cancer in addition to its role in 
cancer glycolysis. The functional involvement of PFKFB3 S-glutathionylation in ROS regulation 
 xiii 
 
would also suggest a possible role for PFKFB3 in cell cycle progression in cancer cells. Together, 
this new understanding of PFKFB3 functions in cancer will contribute to the development of 
appropriate therapeutic strategies for cancer treatment.  
 1 
 
CHAPTER 1: REVIEW OF LITERATURE 
Glycolysis 
  Living cells require energy to function properly under continuously fluctuating 
physiological conditions (Rolland et al. 2001; McCord 2002; Hsu and Sabatini 2008).  To cope 
with the energy demand, cells maintain optimal metabolic condition by continuously adjusting 
their metabolism to the dynamic changes (Bergareche and Ruiz-Mirazo 1999). Oxidation of 
nutrients, such as glucose, fatty acids and amino acids, produces cellular energy in the form of 
adenosine triphosphate, a main chemical energy carrier in all cells (Vander Heiden et al. 2009). 
Glycolysis is a central carbon metabolic pathway in nearly all organisms, in which cellular 
energy is generated by the degradation of glucose into pyruvate or lactate (Figure 1.1) (Welberg 
2010). Moreover, glycolysis provides vitally important precursors for macromolecular synthesis. 
In an aerobic environment, pyruvate molecules are transported to mitochondria and are 
completely oxidized to carbon dioxide and water through the citric acid cycle and the electron 
transport system with the release of energy. Under anaerobic conditions, however, pyruvate is 
converted to lactate in order to regenerate oxidized nicotinamide adenine dinucleotide (NAD+), a 
molecule necessary to continue glycolysis. Glycolysis must be tightly regulated to maintain 
cellular metabolic balance and to optimize the production of energy and essential cellular 
components.  
Fructose-2,6-Bisphosphate 
 Among ten enzyme-catalyzed reactions of glycolysis, the reaction catalyzed by 6-
phosphofructose-1-kinase (PFK-1) is considered the major rate-limiting step of the pathway and 
is tightly regulated.  
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Figure 1.1. Glucose metabolism. Shown are the two interconnected glucose metabolic 
pathways, glycolysis and the pentose-phosphate pathway (PPP); PFKFB, 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase; PFK1, 6-phosphofructo-1-kinase; F1,6P2, fructose-1,6-
bisphosphate; F-2,6-P2, fructose-2,6-bisphosphate; F6P, fructose-6-phosphate; G6P, glucose-6-
phosphate; Ribul-5P, ribulose-5-phosphate. 
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(A) 
 
(B) 
 
Figure 1.2. The most potent allosteric activator of glycolysis, Fructose-2,6-Bisphosphate. 
(A) The chemical structure of fructose-2,6-bisphosphate. (B) Glucose pathways and F-2,6-P2.  F-
2,6-P2 is allosteric activator of 6-phosphofructo-1-kinase (PFK), the rate-limiting enzyme of 
glycolysis and also an inhibitor of Fructose-1,6-bisphosphatase (FDPase), the decreased F-2,6-P2 
activates FDPase, enhancing gluconeogenesis. 
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 PFK-1 catalyzes the first irreversible step of glycolysis, the conversion of fructose-6-phosphate 
(F6P) to fructose-1,6-bisphosphate (F-1,6-P2) by adding a phosphate from ATP. As the most 
important control site in the glycolytic pathway, this step is subject to extensive regulation by 
allosteric activators including the most potent allosteric activator, fructose 2,6-bisphosphate (F-
2,6-P2) (Figure 1.2). 
The cellular concentration of F-2,6-P2 ultimately determines the rate of glycolysis 
because PFK-1 is almost completely inactive without F-2,6-P2 at physiological concentrations of 
its substrates and its known effectors (Reinhart and Lardy 1980).  Binding of F-2,6-P2 greatly 
increases the affinity of PFK-1 for F6P by shifting the equilibrium of PFK-1 conformation from 
low state to that of high affinity for substrates, and it can override inhibition of PFK1 by ATP 
(Furuya and Uyeda 1980).  Moreover, F-2,6-P2 was shown to simultaneously inactivate 
gluconeogenesis, the reverse anabolic process of glycolysis, by inhibiting Fructose-1,6-
bisphosphatase (FDPase), a key regulatory enzyme of gluconeogenesis (Furuya and Uyeda 1981). 
Thus, F-2,6-P2 is thought to play central roles in the orchestration of energy utilization and the 
complex metabolic responses to dynamic cellular conditions by coordinating glycolysis and 
gluconeogenesis (Furuya et al. 1982). Recent studies report that an increase in Fru-2,6-P2 
concentration correlates with cell proliferation and the cell division process (Joaquin et al. 1997; 
Bosca et al. 1985). Tumorigenesis or oncogenic transformation is often associated with elevated 
levels of F-2,6-P2, revealing an important link between metabolism and cell proliferation 
(Colomer et al. 1991; Hue and Rousseau 1993). 
Bifunctional Enzyme, PFKFB 
   The cellular concentration of F-2,6-P2, the most potent activator of glycolysis, is primarily 
regulated by a family of bifunctional enzymes, 6-phosphofructo-2-kinase/fructose-2,6-
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bisphosphatase (PFKFB), which have both kinase and phosphatase activities for F-2,6-P2 
synthesis and degradation (Pilkis et al. 1995).  Having two mutually opposing catalytic domains, 
PFKFB catalyzes both the ATP-dependent phosphorylation of F6P to F-2,6-P2 (2-Kase activity) 
and the dephosphorylation of F-2,6-P2 to F6P (2-Pase activity) (Figure 1.3) (Furuya and Uyeda 
1981).  The 2-Kase domain is located on the N-terminal, which retains the P-loop NTPase fold, a 
distinct motif found in nucleotide-binding proteins (Figure 1.4), whereas the 2-Pase activity of 
domain of the C-terminal domain is structurally and functionally similar to the histidine 
phosphatase family of enzymes (Leipe et al. 2003; Leipe et al. 2002; Rigden 2008).  
 
 
Figure 1.3. The enzymatic reactions of PFKFB, which are responsible for the synthesis and 
degradation of Fructose-2,6-Bisphosphate.  
 
 
 The N-terminal 2-Kase domain is built on a six stranded antiparallel β-sheet, flanked by seven 
α-helices (Kim et al. 2006). A Walker A motif (GXXXXGKT/S) within this fold accommodates 
the phosphate group of ATP which forms a direct substrate-substrate interaction with F6P 
(Walker et al. 1982). The C-terminal 2-Pase domain forms a mixed α/ β structure with a six-
stranded β-sheet, surrounded by α-helices,  and additional  subdomain of two helices that 
contributes to substrate binding. 
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Figure 1.4. The P-loop is involved in binding of ATP. The typical binding of a nucleotide 
triphosphate by the Walker A and B motifs of P-loop is shown (Cavalier 2012). 
 
Four different tissue-specific PFKFB isoforms, encoded by distinct genes, serve tissue-
specific regulation of glycolysis in diverse mammalian cells: liver (PFKFB1), heart (PFKFB2), 
testis (PFKFB4), and cancer cells (PFKFB3) (O. Minchenko et al. 2003). The tissue-specific 
variants of PFKFB are often predominantly expressed, in combination with other isoforms, 
rather than exclusively expressed in human tissues. Despite the high amino acid sequence 
identity in their catalytic domains (>85), the kinase and phosphatase activities varied across the 
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different PFKFB isoforms, among which PFKFB3 has an overwhelmingly high kinase activity to 
phosphatase activity ratio of 700 (Sakakibara et al. 1999). Interestingly, the catalytic activity of 
PFKFB isoforms is critically controlled by reversible phosphorylation and this control is 
particular to each isoform (Figure 1.5) (Van Schaftingen et al. 1981a; Furuya et al. 1982). 
The Liver Isoform (PFKFB1) 
In liver, the open reading frame of gene pfkfb1 encodes the 471 amino acid liver isoform of 
PFKFB, otherwise known as PFKFB1 (Algaier and Uyeda 1988). Having one phosphorylation 
site, Ser32, near the N-terminus, PFKFB1 is subject to large changes in catalytic activity upon 
phosphorylation, shifting its predominant catalytic activity toward 2-Pase from 2-Kase (Figure 
1.6) (El-Maghrabi et al. 1982). Upon stimulation of cAMP signaling pathways by glucagon, 
PKA is activated and phophorylates PFKFB1 to stimulate 2-Pase activity and inhibit 2-Kase 
activity of the enzyme, transforming PFKFB1 into the predominant 2-Pase (Murray et al. 1984). 
This results in a decrease in the concentration of F-2,6-P2 and a subsequent decrease in glycolytic 
flux while enhancing gluconeogenesis in the liver (Van Schaftingen et al. 1981a; El-Maghrabi et 
al. 2001). With this unique alteration of catalytic properties via phosphorylation and 
dephosphorylation, PFKFB1 plays a crucial role in overall glucose homeostasis and carbohydrate 
metabolism in the liver and, ultimately, body. 
The Heart Isoform (PFKFB2) 
   PFKFB2, the gene product of pfkfb2, shares a highly conserved catalytic core with the liver 
isoform (Rider et al. 1985). The heart isoform, PFKFB2, was found to differ from the liver 
isoform in lacking a single phosphorylation site on the N-terminus and containing two sites on 
the C-terminus (Figure 1.6). 
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Figure 1.5. The crystal structures of PFKFB isoforms. Ribbon diagrams of the crystal 
structure of the tissue-specific isoforms of PFKFB. The substrates, Fru-6-P bound to the 
phosphatase domain and ATP or ADP bound to kinase domain are also shown for comparison 
(Cavalier 2012). 
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 The increased cardiac load and ischemia in addition to endocrines can be involved in the 
phosphorylation of Ser466 and Ser483 of PFKFB2, causing an alterations of enzymatic activities 
(Deprez et al. 1997).  
     The phosphorylation of PFKFB2 leads to activation of 2-Kase activity without altering 2-Pase 
activity, which is contrary to the phosphorylation of PFKFB1. In normal conditions, myocardial 
cells produce energy primarily from the oxidant of lipids when oxygen is plentiful. However, 
under conditions of increased epinephrine, cardiac load, or ischemia, myocardial cells show 
abnormal metabolism, a shifting in energy production toward glycolysis through phosphorylation 
of PFKFB2, followed by an increase in 2-Kase activity. This is an important protective 
mechanism for supporting energy demands and thus ensuring the survival of heart cells during 
conditions in which oxidative energy production is impaired (Deprez et al. 1997; Heine-Suner et 
al. 1998). 
The Testis Isoform (PFKFB4) 
The gene product of pfkfb4, the testis isoform of PFKFB, also shares a highly conserved 
catalytic core and C-terminus with the liver isoform (Sakata et al. 1991). However, unlike other 
isoforms, PFKFB4 lacks phosphorylation site and its activity is not subject to regulation by 
phosphorylation (Figure 1.6) (El-Maghrabi et al. 2001).  Testis tissues are known to have a high 
glycolytic activity, caused mainly by a high 2-Kase:2-Pase activity ratio of PFKFB4. 
The Cancer Isoform (PFKFB3) 
PFKFB3, the gene product of pfkfb3, is ubiquitously expressed and has been previously termed 
brain/placental PFK-2, inducible PFK-2 (iPFK-2), ubiquitous PFK-2 (uPFK-2) (Manzano et al. 
1998).  
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Figure 1.6. Regulation of PFKFB activities by Phosphorylation. The unique phosphorylation 
sites of each tissue-specific isoform of PFKFB (Cavalier 2012).   
 
PFKFB3 is termed cancer isoform of PFKFB due to its dominant overexpression and the 
highly activated its activity in proliferating tissues and in various tumor cell lines (Chesney et al. 
1999; Chesney et al. 2005). PFKFB3 expression is induced by mitogenic, inflammatory and 
hypoxia stimuli (hypoxia-inducible transcription factor-1, HIF-1) in several cancer cell lines 
(Dang and Semenza 1999; A. Minchenko et al. 2002; Obach et al. 2004).  PFKFB3 is 
distinguished from other PFKFB isoforms by possessing an overwhelmingly high 2-Kase to 2-
Pase activity ratio of 700:1, allowing for elevated F-2,6-P2 levels which is followed by an 
increase in glycolytic flux (Sakakibara et al. 1999). The 2-Pase domain of PFKFB3 is nearly 
inactive due to a single site sequence difference at Ser302, which is a critical position to stabilize 
the phosphoenzyme intermediate (E-P) during the 2-Pase reaction (Figure 1.7) (Kim et al. 2006). 
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Figure 1.7. Substrate binding and mechanism. (A) Binding of F-6-P. Dot lines represent 
hydrogen bonds. (B) In-line positioning of the bridge oxygen, γ-P, and 2-O of F-6-P. (C) 
Catalytic reaction of PFKFB kinase catalyzing the synthesis of fructose-2,6-bisphosphate (Kim 
et al. 2006; Kim et al. 2007). 
 
  
The varied sequences in the two substrate loops of 2-Kase domain, ATP-loop and F6P-
loop, create longer and more stable loops than those in other isoforms and make the interactions 
between 2-Kinase and substrates (Figure 1.8), ultimately conferring the highest 2-Kase activity 
among members of the PFKFB protein family. The high 2-Kase activity can be increased even 
further through phosphorylation of the C-terminal domain at Ser460 by PKA, PKB, PKC, or 
AMPPK, leading to an elevated 2-Kase to 2-Pase activity ratio up to 3000:1 (Figure 1.6) 
(Sakakibara et al. 1997). In addition, oncogenes including c-myc, c-ras, and c-src have 
complementary effects on cell proliferation and expression of PFKFB3 (Chesney 2006; Telang et 
al. 2006; Dihazi et al. 2003; Shim et al. 1998; Lewis et al. 1997).  Altogether, these unique 
characteristics such as hypoxic regulation of protein expression, mitogen and oncogene-
dependent upregulation, and its predominant 2-Kase activity suggest that PFKFB3 is strongly 
linked to the elevated glycolytic activity within cancer cells. 
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Figure 1.8.  The substrate loops and the 2-Pase domain of PFKFB3.  (A) The ATP and F-6-P 
loops are labeled. To compare the conformational differences, the PFKFB1 structure is also 
superimposed in grey.  (B) The interaction between Y424 form 2-Pase domain and ADP is 
shown.  The 2-Kase domain is in magenta and the 2-Pase in light blue (Kim et al. 2006; Kim et 
al. 2007) . 
 
Tumor Metabolism, Warburg Effect 
   Cancer is a disease caused by uncontrolled cell growth that has the ability to migrate and 
spread to other surrounding tissues and organs (Jones and Thompson 2009). To support the 
requirements of unrestricted cell division and proliferation, cancer cells display dramatic changes 
in energy metabolism and glucose uptake. In a majority of tumor cell types, the metabolic 
alterations, such as increased glucose uptake and enhanced conversion of glucose to lactate, are 
observed in comparison to their normal counterparts (Figure 1.9) (Bauer et al. 2004; 
DeBerardinis et al. 2008). Instead of full respiration, a large number of tumor cells including 
lung, colon, skin, and leukemia exhibit a high rate of glycolysis followed by lactic fermentation 
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even in the presence of abundant oxygen (Gatenby and Gillies 2004; Moreno-Sanchez et al. 
2007). In the 1920s, Otto Warburg initially theorized that mitochondrial respiratory defect may 
be the origin of cancer (Warburg 1956). Thus, this phenomenon of high glycolysis in cancer cells 
is known as “the Warburg effect”, providing an integrated understanding of cancer metabolism 
and metabolic markers of cancer prognosis (Wechalekar et al. 2005). A metabolic shift towards 
aerobic glycolysis is likely to confer a series of advantages to cancer cell. Firstly, despite the 
lower net energy yield as compared to oxidative phosphorylation, the energy production from 
aerobic glycolysis is much faster and safer than aerobic respiration, which produces reactive 
oxygen species (ROS) (Bui and Thompson 2006; Holley et al. 2012). Also, a decreased reliance 
on oxygen for energy generation ensures cancer cell survival and growth under oxygen limited 
condition. Accelerated glycolytic processes provide the necessary precursors for the biosynthesis 
of nucleotides and lipid that are essential for cell division and proliferation (Pfeiffer et al. 2001). 
In addition, a lower intracellular and extracellular pH of tumor tissue, which is established by 
enhancing lactate production, causes apoptosis in neighboring normal cells, enhances invasion, 
and provides tumor protection and resistance from the immune system and cancer drugs 
(Williams et al. 1999). Furthermore, cancer cells outcompetes neighboring normal cells for 
nutrients needed for survival and growth by consuming the majority of substrates (DeBerardinis 
2012). Although an abnormally high glycolytic rate has been consistently shown in a wide 
variety of tumors, the underlying mechanisms responsible for the Warburg effect have remained 
poorly understood. Among the possible causative factors, mitochondrial respiration impairment, 
activation of key oncogenes, and the hypoxic tumor microenvironment are thought to be major 
mechanisms leading to the metabolic adaptation in cancer (Xu et al. 2005). Oncogenes such as c-
myc, c-ras, and c-src often induce upregulation of the majority of glycolytic enzymes, including 
 14 
 
hexokinase-2, lactate dehydrogenase, and PFKFB3 (Levine and Puzio-Kuter 2010). Additionally, 
the activation of hypoxia-inducible factor-1 (HIF-1) plays a key role in the activation of 
glycolysis in cancer (Caro 2001; Brahimi-Horn and Pouyssegur 2006). Although it is constantly 
degraded in normal cells with sufficient oxygen supply, HIF-1α is stabilized in tumors even 
under non-hypoxic conditions. The stabilized HIF-1α causes gene expression of nearly all 
glycolytic proteins and glucose transporters, leading to the Warburg phenotype (Dang and 
Semenza 1999; A. Minchenko et al. 2002). As a result of mitochondrial defects and activation of 
oncogenes and HIF-1, cancer cells mainly rely on enhanced aerobic glycolysis for their energy 
production (Obach et al. 2004). 
 
 
 
Figure 1.9. The metabolic alterations of cancer cells (Cairns et al. 2011). 
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PFKFB3 and Cancer Metabolism 
  The most potent regulator of glycolysis, F-2,6-P2 may contribute to the high glycolytic 
rate of cancers, because, without F-2,6-P2, the bottleneck step catalyzed by PFK-1 is completely 
blocked at physiological concentrations of other substrates, which even exist at abundant levels 
within tumor cells (Hue and Rousseau 1993). Multiple studies have revealed that the F-2,6-P2 
levels are elevated in various cancer cell lines and moreover often accompanied by a high 
proliferative rates, cell-cycle progression, and transformation (Colomer et al. 1987; Hue and 
Rousseau 1993).  Indeed, PFKFB3 that tightly controls cellular F-2,6-P2 concentration has been 
found in rapidly proliferating cells and tumors including breast cancer, leukemia, and colon 
adenocarcinoma, suggesting a possible correlation between PFKFB3 and Warburg effect 
(Chesney et al. 1999; Hamilton et al. 1997). Later studies have shown that PFKFB3 is required 
for possible neoplastic transformation by key regulatory oncogenes of ra8s, c-myc, and src, 
which have been implicated in the Warburg phenomenon (Shim et al. 1998; Telang et al. 2006; 
Lewis et al. 1997). Moreover, the expression of PFKFB3 is highly induced in several cancer cell 
lines by HIF-1 dependent mechanism (Dang and Semenza 1999; A. Minchenko et al. 2002; 
Obach et al. 2004). The suppression of PFKFB3 by gene silencing showed the reduction of 
cellular F-2,6-P2 and modulation of glycolysis, leading to suppression of cancer cell viability 
(Calvo et al. 2006). Recently, we have shown that inhibitors targeting PFKFB3 reduced 
glycolytic flux and resulted in growth inhibition and massive cell death in tumor, verifying a 
critical role of PFKFB3 in the Warburg effect and cancer cell growth.  
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PFKFB3 as a Target in Cancer Therapeutics 
The metabolic alteration that cancer cells exhibit increased glycolysis provides an 
understanding of cancer biology and a basis for clinical diagnosis and therapeutic intervention in 
cancer (Xu et al. 2005; Pelicano et al. 2006). The positron emission tomography (PET) using a 
glucose analog probe, 2-deoxy-2-[18F]fluoro- D-glucose (FDG) is widely used for cancer 
diagnosis based on the high glucose consumption of tumor cells (Wechalekar et al. 2005). 
Selective inhibition of glycolysis to kill cancer cells and the development of therapeutic agents 
targeting glycolytic enzymes are important areas of study based on Warburg effect. Supporting 
this notion, several candidate compounds that inhibit glycolytic enzymes have been identified 
(Xu et al. 2005).  However, the therapeutic implication based on Warburg effect has not been 
successful in clinical trials despite the long history because of difficulties in target hunting. 
Suppressing glycolysis by selective inhibition of PFKFB3 isozyme must be a promising 
therapeutic target because PFKFB3 is the causative protein for the Warburg effect and its 
inhibition would effectively shut down glycolysis. This therapeutic strategy will be ubiquitously 
effective since both the Warburg effect and the overexpression of PFKFB3 have been shown to 
be ubiquitous to almost all cancer types (Atsumi et al. 2002; Atsumi et al. 2005). Moreover, 
PFKFB3 gene silencing studies, which results in a reduction of glycolysis and suppression of 
cancer cell viability and growth, validate targeting PFKFB3 as a cancer therapeutic strategy 
(Calvo et al. 2006). Clem et al. identified 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) 
as a possible PFKFB3 inhibitor through in silico techniques using the receptor structure 
predicted from another isoform PFKFB4, showing reduced glycolytic flux and tumor growth in 
several cancer cell lines (Clem et al. 2008). However, for target specificity and drug efficacy, the 
development of PFKFB3 inhibitors should be guided by the ‘true’ structure rather than predicted 
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structures from another isoform. We have found novel competitive inhibitors of PFKFB3 and the 
structures of the PFKFB3 in complex with the inhibitors, which will establish a foundation for 
the structure assisted development and optimization of effective therapeutic agents targeting 
PFKFB3 selectively. 
Oxidative Stress 
Oxygen is essential for aerobic organisms to sustain their lives, but it can be harmful to 
all organisms which use oxygen. As a consequence of this “Oxygen Paradox”, oxidative stress 
occurs and constitutes the main threat to aerobic cells (Myers et al. 1985). Oxidative stress have 
been described as an imbalance between the production of reactive oxygen species (ROS) and 
the activity of antioxidant defense systems that detoxify cellular ROS (Valko et al. 2006). 
Typically, ROS are highly reactive oxygen molecules than the ground-state oxygen, O2, that 
have one or more unpaired electrons in their outer valence orbital. When molecular oxygen (O2) 
is partially reduced via various physiological processes, highly reactive intermediates such as 
superoxide anion (O2•-), hydroxyl radical (•OH) and singlet oxygen (
1O2), as well as non-radical 
hydrogen peroxide (H2O2) are produced within cells (Figure 1.10) (Rodriguez and Redman 
2005).  
 
 
Figure 1.10. Mechanism of ROS production. Production of different ROS by sequential 
ground-state oxygen reduction pathway (Rodriguez and Redman 2005). 
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Among these ROS, superoxide anion is a mild reactant in physiological condition with 
one exception that it interacts with nitric oxide (NO) to transform superoxide into a highly 
reactive compound (Georgakilas and Panayiotidis 2012; Lawless et al. 2010).  Superoxide anion, 
a poorly membrane-permeable molecule, can be converted to hydrogen peroxide enzymatically 
by superoxide dismutase (SOD) and non- enzymatically (Temple et al. 2005). Hydrogen 
peroxide is more properly a pro-oxidant or non-radical potent oxidizing agent that can freely 
diffuse through biological membranes (Temple et al. 2005). Although hydrogen peroxide itself is 
not highly reactive, it becomes to the deadly damaging compound, hydroxyl radical, when 
reacting with superoxide anion or when Fe2+ is present via the so-called Haber-Weiss/Fenton's 
reactions (Droge 2002). The highly damaging molecule, hydroxyl radical, can damage 
surrounding cellular constituents such as amino acids, carbohydrates, lipids and nucleic acids, 
but has a very short half-life (10-9 s) that limits its diffusion of  from its site of formation, 
limiting the spatial extent of cytotoxicity (Figure 1.11) (Giorgio et al. 2007). In living cells, the 
generation of ROS can be caused by several sources. The source of ROS within cell is the 
mitochondria, the primary source of free radicals through the leakage of electrons from the 
respiratory chain, and other cellular source including peroxisomes, NADPH oxidase, xanthine 
oxidase and 5-Lipoxygenase as well as fatty acid-CoA oxidases (Koenitzer and Freeman 2010; 
Perera and Bardeesy 2011).  ROS also can be produced by exogenous sources such as 
environmental agents, xenobiotics, chemotherapeutics, ionizing radiation, and UV radiation 
(Figure 1.12).  Recently, it has been demonstrated that relatively low levels of ROS control many 
different cellular processes including stress response, pathogen defense and systemic signaling as 
well as cell proliferation (Leonarduzzi et al. 2011; Rudolph and Freeman 2009). 
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Figure 1.11.  Longevity and cellular concentration of reactive oxygen species. T1/2 is the half-
life (Giorgio et al. 2007).  
  
 20 
 
 
Figure 1.12. Intrinsic and extrinsic source of ROS (Perera and Bardeesy 2011). 
 
 
Although ROS have been regarded as being random and stochastic, accumulating 
evidence suggests that ROS are tightly regulated in their production and even behave as a 
specific signaling molecules (Mailloux and Harper 2012; Mittler et al. 2011). Because they are 
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highly reactive with biomolecules and able to form chain reactions to generate more radicals, 
ROS can be particularly harmful as the levels of ROS increase. Severe oxidative stress can cause 
cellular apoptosis and/or tissue necrosis(Ray et al. 2012). Moreover, ROS mediated cellular 
damage, especially ROS induced genomic instability due to mutagenic modification and 
chromosomal rearrangements, is believed to lead to impaired physiological function and human 
degenerative diseases (Figure 1.12). 
ROS and Cancer 
Studies have shown that ROS and oxidative stress are associated with cancer by revealing 
that cancer cells have higher levels of ROS than normal cells (Lawless et al. 2010; Visconti and 
Grieco 2009). However, it remains unclear whether an increase in ROS is a cause or a 
consequence of cancer progression (Benz and Yau 2008; Dreher and Junod 1996). Tumorigenic 
conditions including abnormal metabolic patterns, mitochondrial malfunction, hypoxia, matrix 
detachment, and inflammation have been linked to enhanced ROS production (Figure 1.13) 
(Trachootham et al. 2009; Valko et al. 2006). Upregulation of transcription factors such as NF-
κB and AP-1 in cancer also can lead to an increase in ROS generation (Benhar et al. 2002). As a 
consequence, these chronic increases in ROS contribute to genetic instability by causing strand 
breaks, alterations in guanine and thymine bases, and sister chromatid exchanges, and thus 
increase the malignant potential of cancer cells (Figure 1.14) (Perera and Bardeesy 2011; Wu 
2006). Recently, it was shown that ROS promote cancer cell proliferation, tumor initiation and 
progression (Perera and Bardeesy 2011). Cancer cell proliferation in response to ROS is thought 
to be due to the ROS-induced activation of c-Jun amino-terminal kinase/stress-activated protein 
kinase (JNK/SAPK), Rac1, NADPH-oxidase, and mitogen-activated protein kinases pathways 
(Benhar et al. 2002; Ushio-Fukai 2009). In addition, an increase in ROS production has been 
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shown to induce cell cycle progression, especially by promoting G1/S phase transition 
(Shackelford et al. 2000; Deng et al. 2003; Kopnin et al. 2004). 
 
 
 
Figure 1.13.  Enhanced production of ROS in cancer (Trachootham et al. 2009). 
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Figure 1.14.  ROS adaptation in cancer progression. The ROS adaptation may promote cancer 
development including proliferation, senescence evasion, angiogenesis and metastasis, and drug 
resistance. (Trachootham et al. 2009). 
 
Chronic oxidative stress leads to adaptive responses within cancer cells which results in 
increased resistance to chemotherapy by upregulating expression of the multidrug-resistance 
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efflux pump, P-glycoprotein. Oxidative stress also increases the blood supply to tumor cells by 
stimulating angiogenic factors IL-8, vascular endothelial growth factor (VEGF) and matrix 
metalloproteinase-1 (MMP-1) for vessel growth (Wu 2006; Chen et al. 2012). 
Additionally, ROS have been shown to facilitate invasion and metastasis by activating 
p38 MAPK and Rac1 that alter arrangements and recognition of actin cytoskeleton (Ishikawa et 
al. 2008). Moreover, ROS within the cancer microenvironment can directly damage endothelial 
cells to increase vascular invasion. Although it appears to support tumor progression, ROS can 
cause detrimental oxidative stress that damage cellular components and lead to cell death when 
the level of ROS becomes excessive (Wu 2006).  P53 tumor suppressor protein and pro-
apoptotic signaling molecules, such as ASK1, JNK and p38, are known to be involved in the 
ROS-induced apoptosis (Simon et al. 2000; Tanaka et al. 2002). 
Glutathione 
Although it appears to support tumor progression, ROS can cause detrimental oxidative 
stress that damage cellular components and lead to cell death when the level of ROS becomes 
excessive. The overproduced ROS, especially in cancer cells, must be tightly regulated because 
cancer cells experience enormous amounts of oxidative stress, compared to normal cells (Finkel 
and Holbrook 2000). Biological mechanisms of antioxidant have evolved to protect cells from 
the toxic effects of ROS and to maintain the redox balance (Di Pietro et al. 2010; Balendiran et al. 
2004). The term antioxidant refers to any compound that functions to quench free radicals and to 
interrupt the cascades of uncontrolled oxidation. Among the numerous antioxidant systems are 
several antioxidant enzymes, such as superoxide dismutase, glutathione peroxidase and catalase, 
and small molecules including glutathione and ascorbate (Fridovich 1995; Valko et al. 2007). 
One of the major low-molecular-weight antioxidants is the tripeptide glutathione (γ-glutamyl-
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cysteine-glycine) (GSH), in which the sulfhydryl (thiol) group (SH) on the cysteine serves as a 
proton donor and plays an important role of ROS scavenging (Figure 1.15) (Meister and 
Anderson 1983; Lushchak 2012). GSH is ubiquitously found in most tissues at millimolar 
concentration (1–10 mM), allowing it to function as the most highly concentrated intracellular 
antioxidant and important cofactor for antioxidant enzymes (Lushchak 2012).  
 
 
Figure 1.15. Chemical structure of glutathione. (A) Reduced state of glutathione and (B) 
oxidized state, glutathione disulphide (Lushchak 2012). 
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Cellular GSH is synthesized within cells in two consecutive enzymatic reactions that use 
ATP. Cysteine and glutamate are first joined through a peptide bond with the amide on glutamate 
side chain by the enzyme gamma-glutamylcysteine synthetase. Then, the intermediary product, 
gamma-glutamylcysteine is used by glutathione synthetase to form GSH by adding glycine. The 
availability of cysteine controls the reaction rate of GSH synthesis since cysteine is only 
available at micromolar range compared to the abundance of glycine and glutamate (Runnegar et 
al. 1995). Glutathione can exist in two states interchangeably, reduced (GSH) and oxidized 
(glutathione disulphide: GSSG) states in which it forms a stable disulfide-linked complex. 
Glutathione is present inside cells in the unbound and proteins bound forms, primarily in the 
reduced state, GSH, which is 90-95% of the total glutathione (Lushchak 2012).  
 
 
Figure 1.16. ROS protective mechanism of GSH. GPx, glutathione peroxidase; GR, 
glutathione reductase; G6PD, glucose 6-phophate dehydrogenase (Lushchak 2012). 
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The ROS protective mechanism of GSH is achieved by the formation of mixed disulfides 
(GSSG), which is called thiol/disulfide exchange reaction (—SH —S-S—), donating an electron 
to ROS (Figure 1.16). The regeneration of GSH from GSSG is catalyzed by the enzyme 
glutathione reductase at the expense of reduced nicotinamide adenine dinucleotide phosphate 
(NADPH), making GSH as a recyclable antioxidant compound (Pastore et al. 2003). Thus, the 
ratio of GSH to GSSG within cells is often used as a sensitive indicator of oxidative stress. 
Besides redox cycling, GSH participates in diverse biological processes (Franco et al. 2007). For 
example, GSH has profound importance for maintaining the essential thiol status of proteins and 
other cellular components and for the operation of some transcription factors, especially which 
involved in redox signaling.  GSH can detoxify heavy metals, organic xenobiotics, and many 
other toxic metabolites which are produced as side product of cellular metabolism (Cooper and 
Kristal 1997). Its ability to interact with some metal ions allows to participate in the maturation 
of iron-sulfur clusters of diverse proteins and in copper and iron transfer. 
S-Glutathionylation, a Post-Translational Modification 
     Protein post-translational modifications are key mechanisms to increase proteomic 
diversity and to regulate cellular physiology and function. Numerous different types of protein 
modification have been studied, including acetylation, adenylation, glycosylation, methylation, 
and phosphorylation. These modifications often occur at selected residues of proteins, allowing 
the unique function and regulation of a protein. Glutathione also plays an important role in the 
post-translational modification, called S-glutathionylation (Dalle-Donne et al. 2007; Dalle-
Donne et al. 2009). This process generates glutathionylated proteins (PSSG), in which a mixed 
disulfide bond has been formed between GSH and the thiol group of cysteine residues in proteins 
(Figure 1.17) (Dalle-Donne et al. 2009). Protein S-glutathionylation may proceed through several 
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mechanisms. S-glutathionylated proteins can result from a direct thiol/disulfide exchange 
between protein thiols and GSSG or PSSG (Shelton and Mieyal 2008; Dulce et al. 2011).   
 
 
Figure 1.17. S-glutathionylation, a Post-translational modification of protein thiols.  
Grx, glutaredoxin; -SH, reduced protein thiol; -S-NO, S-nitrosylated protein; -S-SG, S-
glutathionylated protein; ROS, reactive oxygen species (Dalle-Donne et al. 2009). 
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ROS-induced oxidation of cysteine residues of proteins leads to the formation of sulfenic, 
sulfinic, or sulfonic acid derivatives and, among which partially oxidized protein thiols can 
interact with GSH generating glutathionylated proteins (Pastore and Piemonte 2012). With the 
triggering of many oxidant molecules, the interaction between a free protein cysteine residue and 
GSH can induce its S-glutathionylation (Dalle-Donne et al. 2007). Furthermore, an enzyme, 
Glutathione S-transferase, is considered likely to catalyze the formation of a mixed disulfide 
bond between protein thiols and GSH (Cotgreave et al. 2002; Shenton et al. 2002). The 
glutathionylation residue, cysteine, is often found in the active site of numerous proteins, and 
moreover, modification of cysteine side chains in proteins causes a conformational change 
although some proteins may not contains cysteine in the active site (Dalle-Donne et al. 2009; 
Mieyal et al. 2008). Therefore, protein S-glutathionylation, the modification of cysteine thiols by 
glutathione, can potentially affect protein activity and some of the targeted proteins lose 
functional activity whereas others can be activated. This characteristic of S-glutathionylation 
allows it to be involved in diverse physiological processes including cell growth, cell cycle 
progression, differentiation, transcriptional activity, cytoskeletal functions, and metabolism 
(Dalle-Donne et al. 2009). S-glutathionylation can be reversed through mechanisms involving 
direct thiol/disulfide exchange reactions with GSH or an enzymatically mediated reaction by 
glutaredoxin reductase and thioredoxin reductase. The reversibility of S-glutathionylation is 
required to be an important mechanism preventing ROS-induced irreversible protein inactivation 
and permanent damage under oxidative stress because the functional activity of glutathionylated 
proteins can be restored simply by removing glutathione from protein, particularly in response to 
sudden changes in ROS levels (Cotgreave et al. 2002; Shenton et al. 2002). A number of proteins 
have been shown to undergo glutathionylation, including several metabolic enzymes (enolase, 
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aldolase, 6-phosphoglucolactonase, adenylate kinase, phosphoglycerate kinase, triose phosphate 
isomerase, and pyrophosphatase), cytoskeletal proteins (myosin, tropomyosin, profilin, and 
actin), redox enzymes, stress proteins (HSP70 and HSP60), and fatty acid binding protein 
(Cotgreave et al. 2002; Dalle-Donne et al. 2009; Shenton et al. 2002). However, much remains to 
be learned about regulation and the functional consequence of ROS-mediated S-glutathionylation. 
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CHAPTER 2: STRUCTURE-BASED DEVELOPMET OF SMALL MOLECULE 
PFKFB3 IHIBITORS: A FRAMEWORK FOR POTETIAL CACER THERAPEUTI 
C AGET TARGETIG THE WARBURG EFFECT 
Introduction 
Unlike normal cells, cancer cells have been noted to shift their energy metabolism toward 
glycolysis (Jones and Thompson 2009). This phenomenon, originally termed the Warburg effect 
and this transition allows cancer cells to satisfy increased biosynthetic requirements for biomass 
and energy (Vander Heiden et al. 2009; Warburg 1956). Studies have consistently shown an 
abnormally high glycolytic rate in a wide spectrum of human cancers but the causative 
mechanisms responsible for this metabolic adaptation remain poorly understood (Garber 2006; 
Hsu and Sabatini 2008). Among the possible mechanisms, mitochondrial respiratory defects and 
hypoxia in the tumor microenvironment are attributed as two major factors for the Warburg 
effect (Gottlieb and Tomlinson 2005; Polyak et al. 1998; Pouyssegur et al. 2006).  
Despite the complexity and obscurity of underlying mechanisms responsible for the 
Warburg effect, the metabolic consequences are a consistent transformation toward glycolysis as 
the major source of ATP production (DeBerardinis et al. 2008; Garber 2006). This metabolic 
abnormality of cancer cells provides a biochemical basis to preferentially suppress progression of 
malignant cells by selective inhibition of glycolysis (Pelicano et al. 2006; Tennant et al. 2010; 
Xu et al. 2005). 
 
This chapter first appeared as “M Seo; YH Lee, et al. (2011) Structure-based development of 
small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting 
the Warburg effect. PloS one 6(9):e24179”. The “Material” was reproduced with permission of 
the journal PLoS One. 
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In the glycolysis pathway, phosphofructokinase-1 (PFK-1) catalyzes the major rate-
limiting step that converts fructose-6-phosphate (Fru-6-P) to fructose-1,6-bisphosphate (Fru-1,6-
P2) and is allosterically regulated by fructose-2,6-bisphosphate (Fru-2,6-P2) (El-Maghrabi et al. 
2001; Pilkis et al. 1995). Under abundant energy supply, high levels of ATP strongly inhibit 
PFK-1 activity; however, Fru-2,6-P2 can override this inhibitory effect and enhance glucose 
uptake and glycolytic flux (Van Schaftingen et al. 1981b).  
Not surprisingly, Fru-2,6-P2 synthesis is up-regulated in many cancer cell lines, suggesting that 
selective depletion of intracellular Fru-2,6-P2 in cancer cells may potentially be used to impede 
glycolytic flux and suppress malignant cell  survival and progression (Hue and Rousseau 1993; 
Nissler et al. 1995; Telang et al. 2006).  
A family of bifunctional enzymes, 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatases (PFKFB1-4), are responsible for the intracellular levels of Fru-2,6-P2 (O. 
Minchenko et al. 2003; Rider et al. 2004; Telang et al. 2006). Among these isozymes, PFKFB3 
is dominantly over-expressed in thyroid, breast, colon, prostatic, and ovarian tumor cell lines 
(Atsumi et al. 2002; Calvo et al. 2006; Telang et al. 2006). Recent studies have shown that 
induction of PFKFB3 expression by HIF-1 under hypoxic condition is followed by increased 
invasive potential and resistance to chemotherapies (Atsumi et al. 2002; A. Minchenko et al. 
2002). Taken together, these studies suggest PFKFB3 is a potential target for a new class of anti-
neoplastic agents that prevent onset of the cancer-specific glycolysis by inhibiting the Fru-2,6-P2 
surge and, eventually, induce death of cancer cells. Accordingly, inhibition of PFKFB3 as a 
therapeutic strategy for cancer has been suggested (Calvo et al. 2006).  
Despite the potential merits, exploitation of PFKFB3 for cancer therapy has remained 
poor. Clem et al (2008) reported a pyridinyl-containing compound as a possible PFKFB3 
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inhibitor, based on the receptor structure predicted from that of PFKFB4 (Clem et al. 2008).  
Although promising, inhibitors based on structures other than the true PFKFB3 enzyme may lack 
specificity and limit strategic improvement of inhibitor potency. We were able to overcome such 
an inborn defect by engaging in the structural studies of PFKFB3 and its complexes with ligands. 
In this report, we have identified N4A as a novel competitive inhibitor and tested its inhibitory 
effect on PFKFB3 activity. To understand the molecular mechanism of inhibitor-recognition by 
PFKFB3, we determined the structure of the PFKFB3 in complex with N4A. Guided by the 
structural basis for inhibitor binding, we were then able to optimize N4A, using similarity search 
and computational evaluation, resulting in a follow-up lead compound with a 5-fold 
improvement in potency. 
In addition to the molecular mechanism of PFKFB3 inhibition and inhibitor improvement, 
we also investigated the inhibition of Fru-2,6-P2 production and glycolysis in HeLa cells by the 
PFKFB3 inhibitor treatment. The novel PFKFB3 inhibitors, N4A and YN1 reduced the Fru-2,6-
P2 levels and glycolytic flux, resulting in growth inhibition of tumor cells and massive cell death. 
These results provide not only evidence that validates targeting of  PFKFB3 but also the first 
direct structural insight into the protein inhibitor interactions, establishing a foundation for 
structure-assisted optimization and development of novel PFKFB3 inhibitors as 
chemotherapeutic agents for cancer. 
Results 
Overall Strategy for Inhibitor Screening and Improvement 
A schematic flow diagram describing our strategy adopted for discovery and 
improvement of the PFKFB3 inhibitors is shown in Figure 2.1. Candidates for a lead compound 
were selected from computational screening  using the crystal structure of PFKFB3 which we 
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have previously determined to 2.1 Å resolution (Kim et al. 2006) was used as molecular sieve of 
screening (A). The resulting hit compounds from this molecular sieve were evaluated by 
enzymatic inhibition assay and compounds with the highest inhibition activity were selected as 
lead molecules after consideration of drug-likeliness (B). Next, detailed kinetic properties were 
characterized (C) and the biological effects on human adenocarcinoma cells were investigated by 
measuring glycolytic flux, growth inhibition, and cell death (D). To understand the molecular 
basis of the inhibition of PFKFB3, X-ray crystallographic structure analysis of the 
PFKFB3•inhibitor complex was carried out (E). Based on the molecular information gained 
from Step (E), we performed a search for novel derivative compounds with improved potency, 
using the lead compound as a template (F). The resulting compounds from this similarity search 
were evaluated through computational docking using FlexX (Gohlke et al. 2000) (A) and the best 
optimized compound was passed through this selection process again. Through iterative cycles 
of these processes, we were able to obtain a compound with inhibitory activity orders of 
magnitude above the initial lead and which exhibits potent PFKFB3 inhibition in vitro. 
Inhibitor Screening and Binding Properties 
During our previous study, several compounds capable of binding to the Fru-6-P pocket 
of PFKFB3 were identified from virtual screening. To confirm the inhibitory activities and to 
eliminate false positives from these drug candidates, PFKFB3 inhibition was tested at 10µM 
each of the compounds (Figure 2.2A). 
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Figure 2.1 Flowchart showing the overall strategy used for development of the PFKFB3 
inhibitors. 
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Figure 2.2 Experimental evaluations of the hit compounds. (A) Inhibition potencies of the 
candidate compounds. The magnitudes of inhibition by compounds at 10 µM each are measured 
through the enzyme assay and presented as percentiles against the control (□). A same 
experiment was also performed in the presence of 0.1% Tween-20 (■), to eliminate false 
positives caused by nonspecific hydrophobic interactions. (B) Structures of the PFKFB3 
inhibitors.  
 
 To prevent non-specific inhibition caused by random hydrophobic interactions between inhibitor 
and protein, a same test was performed in the presence of 0.1% Tween-20. Among the tested 
compounds, ZINC04887558 (N4A,5,6,7,8-tetrahydroxy-2-(4-hydroxyphenyl)chromen-4-one) 
inhibited enzyme activity greater than 65% under substrate-saturating conditions and this 
inhibition was not affected by the presence of Tween-20. We selected N4A as an initial ‘lead’ 
(Figure 2.2B). The subsequent kinetic study revealed that N4A inhibits PFKFB3 with an IC50 
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value of 2.97±0.16µM (Table 2.1). A steady state inhibition study showed that N4A inhibits 
PFKFB3 as a competitive inhibitor against Fru-6-P with a Ki of 1.29 ± 0.26µM, as expected from 
virtual screening and as demonstrated in a Lineweaver–Burk plot (Figure 2.3A).   
Improving the inhibition efficacy of the lead compound, N4A, by structure-guided 
optimization is an important goal of this study. As the details will be discussed in the following 
sections, only a brief end result is introduced here for early comparisons. Two additional N4A 
inhibitors, YN1 (7,8-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one) and YZ9 (ethyl 7-hydroxy-
2-oxochromene-3-carboxylate) (Figure 2.2B) have been obtained using structure-guided 
optimization. As summarized in Table 2.1, YN1 exhibitsIC50=0.67µM and Ki=0.24 ± 0.03µM, 
showing a 5-fold increase in inhibition. Compound YZ9 shows even greater inhibition—one 
order of magnitude over the starting lead, N4A. All the tested compounds are soluble in various 
aqueous solutions up to 50 µM ranges in the presence of <1% dimethyl sulfoxide (DMSO). 
The lead compound, N4A, and a derivative, YN1, were tested for their inhibitory effects on 
other human PFKFB isoforms. The inhibitors had a stronger effect on PFKFB3 than on other 
PFKFB isoforms. At twice the IC50 for PFKFB3 where PFKFB3 was over 80% inhibited, N4A 
exhibits less than 50% inhibition and YN1 shows less than 40% inhibition on PFKFB1, PFKFB2 
and PFKFB4 (Figure 2.3B). N4A and YN1 are comparatively selective inhibitors of PFKFB3. 
Improving the isoform specificity must be the main goal of next stage optimization and such 
efforts are being made. 
Effects of 4A and Y1 on the Fru-2,6-P2 levels, Glycolysis, and Cell Growth 
We next investigated effects of applying the N4A and YN1inhibitors to live HeLa cells.  
Inhibition of PFKFB3 is expected to cause a decrease in the levels of Fru-2,6-P2 in HeLa cells.  
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Figure 2.3 The competitive inhibition by 4A and Y1 against Fru-6-P (A) Lineweaver-
Burk plots showing the competitive inhibition by N4A against Fru-6-P. The inhibitor 
concentrations used were: 0 µM (■), 1 µM (○), 2 µM (▲), and 3 µM (□) of N4A. They are also 
labeled next to individual plots. (B) Lineweaver-Burk plots showing the competitive inhibition 
by YN1 against Fru-6-P. The inhibitor concentrations used were: 0 µM (■), 1 µM (○), 2 µM (▲), 
and 3 µM (□) of N4A.  (e) Selectivity of N4A and YN1 on PFKFB isoforms. Results are 
expressed as percent inhibition at twice the IC50 concentration against PFKFB3 (N4A = 6µM, 
YN1 =1.3µM). 
 
After an 8hour exposure to N4A and YN1, Fru-2,6-P2 were reduced approximately 20%; 
after a 48-hour exposure, Fru-2,6-P2 was reduced over 40% (Figure 2.4A).  Down-regulation of 
the Fru-2,6-P2 levels by N4A and YN1 was accompanied by decreased glycolysis, as expected. 
The decrease in the Fru-2,6-P2 levels following exposure to N4A and YN1 led to a decrease in 
lactate production, which was reflected by a greater than 30% decrease in lactate secretions. 
Taken together, these data suggest N4A and YN1 inhibit PFKFB3 resulting in suppression of 
glycolysis (Figure 2.4B).   Increased Fru-2,6-P2 levels preceded by increased glycolysis often 
accompanies  the proliferation of transformed cells, including cancer cells (Vander Heiden et al. 
2009). We examined the effect of the PFKFB3 inhibitors, N4A and YN1, on the proliferation rate 
of human adenocarcinoma cells. 
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Figure 2.4 The effects of the PFKFB3 inhibitors on the Fru-2,6-P2 levels, the lactate 
secretions, and the cell growths. The Fru-2,6-P2 levels (A) and the levels of secreted lactate (B) 
were determined enzymatically at time points 0, 4, 8, 12, 24, or 48 hours after the inhibitor 
treatments of HeLa cells. The results were normalized to the sample protein concentrations and 
expressed as a ratio to the value of vehicle-treated. Data are means ± S.E.M. from at least three 
experiments. Time-dependent effects of 25 µM each of N4A (  ) and YN1 ( ) on the 
cellular Fru-2,6-P2 levels (A) and the lactate secretions (B) are shown. (C) Growth inhibition by 
N4A, YN1, and YZ9 on HeLa and T47D cells. Cell numbers were assayed over 36 hours by the 
trypan blue counting or XTT assay. Data points are expressed as % cell growth of control 
containing vehicle against logarithmic scale of inhibitor concentrations. Error bars stand for 
intraexperimental replicates standard deviation. 
 
Treatments with 25µM each of N4A and YN1 caused 70% and over 90% reductions, 
respectively, in cell proliferation, when compared to unexposed cells (Figure 2.4C). The results 
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of cell growth inhibition assays consistently confirmed that inhibition of PFKFB3 by N4A and 
YN1 suppresses cellular energy metabolism and, ultimately, cell growth and that YN1 is a more 
potent inhibitor with a GI50 of 8.2±0.8µM compared with N4A (GI50= 14.2±1.5µM) (Table 2.1). 
N4A and YN1 were also able to inhibit soft agar colony formation in HeLa cells (Figure 2.5). 
HeLa cells were plated in soft agar with different concentrations of N4A or YN1 and grown for 3 
weeks to allow colony formation. Both compounds significantly inhibited colony formation at 25, 
50 and 100µM. Colony formation was inhibited by 64% and 79% in the presence of 25µM N4A 
and YN1, respectively. 
 
Table 2.1. The kinetic and biological properties the PFKFB3 inhibitors.  
 
 
Inhibitor 
 
IC50 [µM] 
 
Ki [µM] 
 
Inhibition 
 
GI50[µM] 
 
N4A 
 
 
2.97±0.16  
 
1.29±0.26 
 
Competitive to Fru-6-P 
 
14.2±1.5 
 
YN1 
 
0.67±0.08 
 
0.24 ± 0.03 
 
Competitive to Fru-6-P 
 
8.2±0.8 
 
YZ9 
 
0.18 
 
0.094 
 
Competitive to Fru-6-P 
 
2.7±0.2 
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Figure 2.5. Treatment of HeLa cells with 4A and Y1 inhibits soft agar colony formation. 
(A) Anchorage-independent cell growth in soft agar. HeLa cells were grown in soft agar for 21 
days in the presence of the indicated concentrations of N4A and YN1 respectively (20X). (B) 
Statistical analysis of the experiment. Columns, mean (n=5); bars, SD.  
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Figure 2.6 Induction of cell death in HeLa cells by the PFKFB3 inhibitors, 4A and Y1. 
The cells were treated with two different concentrations of inhibitors, 25 µM and 50 µM. (A) 
Induced cell death at two different concentrations of N4A was measured by flow cytometry after 
double staining with Annexin V and PI. (B) Quantitation of the flow-cytometric data (mean ± 
SD) showing a dose-related effect of N4A. (C) Cytograms of YN- induced cell death and (D) 
quantitation of the flow-cytometric data. 
 43 
 
To further investigate the mechanism responsible for the anti-proliferative effect of the 
PFKFB3 inhibitors, flow-cytometric analysis of cell death was performed. The results indicate 
that N4A and YN1 induced both apoptotic and necrotic cell death. This mixed pattern is related 
to the nature of apoptosis, which, unlike necrosis, is an ATP-dependent process (McConkey 
1998; Richter et al. 1996). Cell death induced by the PFKFB3 inhibitors should correlate with 
their ability to deplete cellular ATP and depletion of ATP favors death by necrosis as previously 
speculated (McConkey 1998; Richter et al. 1996; Xu et al. 2005). Our data supports this 
argument: at a relatively low concentration (25µM) of N4A or YN1, an environment in which 
depletion of cellular energy depletion is moderate, cells were found to be prone to apoptosis, 
whereas, at higher concentrations (50µM) of inhibitors, death by necrosis was significantly 
increased due to insufficient cellular energy to support the apoptotic process (Figure 2.6).  
Structure of the PFKFB3-4A complex 
We wished to use the N4A inhibitor as a lead for structure-guided optimization of further 
inhibitors. To facilitate this task, it was necessary to determine the molecular characteristics of 
N4A binding to PFKFB3 by crystallizing human PFKFB3 in the presence of N4A. We 
determined the structure of this complex to 2.4Å resolution by a method of molecular 
replacement using the first PFKFB3 structure (PDB code: 2AXN) as a search model (Kim et al. 
2007). An |Fo|− |Fc| omit map enabled unambiguous placement of N4A into theFru-6-P binding 
pocket of the kinase domain of PFKFB3 (Figure 2.7A). The N4A located at the Fru-6-P pocket 
could be superimposed onto the Fru-6-P modeled in the structure of PFKFB3 in a ternary 
complex with AMPPCP and Fru-6-P (PDB code: 2DWP) (Kim et al. 2007). This structure 
provides clear evidence, supporting the kinetic observations that N4A competes with Fru-6-P for 
the same binding pocket in PFKFB3 (Figure 2.7B,C and 2.8A).  
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Figure 2.7 Structure of PFKFB3 in complex with inhibitors. (A) Ribbon diagram of the 
crystal structure of the PFKFB3•N4A complex. N4A bound to the PFKFB3 Fru-6-P site in the 2-
Kase catalytic pocket is shown with a concomitant ǀFoǀ-ǀFcǀ omit map at a 2.5 level. The Fru-6-P 
bound to the 2-Pase domain is also shown in gray for comparison. (B)The interactions between 
N4A and PFKFB3 are shown. Hydrogen bonds are shown as yellow dotted lines and a Cation-π 
interaction is represented by a red broken line. (C) The water-mediated hydrogen bonds between 
PFKFB3 and N4A are shown in yellow dotted lines.  
 
 As shown in Figure 2.7B and 2.8A, N4A is anchored to the Fru-6-P pocket via hydrogen bonds 
with Arg74, Asp124, Thr126, and Arg132. The phenol moiety of N4A is unfavorably located in 
the pocket where the 6-phosphate moiety of Fru-6-P interacts through a hydrogen bond with 
Arg132 and results in Arg132 adopting a different conformation in the N4A complex. 
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Figure 2.8 4A andY1 bound to the Fru-6-P site. (A) Inhibitor-induced local conformational 
changes around the N4A binding groove. Comparison of the structures of the 
PFKFB3•AMPPCP•Fru-6-P complex (dark gray) and the PFKFB3•N4A complex (color) was 
made. (B)YN1 bound to the same pocket with a ǀFoǀ-ǀFcǀ omit map at 2.5 level is shown. 
Hydrogen bonds between YN1 and PFKFB3 are shown as yellow dotted lines and Cation-π 
interactions as red broken lines. 
 
 The chromone moiety of N4A occupies the same position as the fructose moiety. Here, two of 
N4A’s hydroxyl groups (OAF and OAA) mimic the hydrogen-bonding pattern of the hydroxyl 
groups at the C3 and C4 positions of the fructose moiety. The binding competence of N4A is 
further strengthened by a number of water-mediated hydrogen bonds between the hydroxyl 
group of the N4A with Thr48, Arg98, Asp124, Thr126, and Tyr193 and the conformational 
changes induced upon the binding (Figure 2.7C). The protein ligand interactions are summarized 
in Table 2.2. 
When compared with PFKFB3 complexed with AMPPCP and Fru-6-P (PDB 
code:2DWP), the N4A-PFKFB3 complex induces no significant difference in global structure. 
However, the differences around the F-6-P binding pocket were evident as shown in Figure 2.8A. 
Upon N4A binding, the Arg132 side chain swings out about 3.5 Å from the position for Fru-6-P 
site, offering space to accommodate N4A. As a consequence, Glu131 in the same helix moves 
toward the F-6-P pocket by ~2 Å.  
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Table 2.2 Interactions between the inhibitors and PFKFB3 
 
 
 
 
The guanidino group of Arg75 moved 1.5 Å toward the inhibitor from its original 
position, implying that the closer positioning of Arg75 stabilizes inhibitor binding. The phenol 
Protein residue Water Inhibitor 
4A 
Type of interaction Distance 
(Å) 
Arg74 
 
NE 
NH2 
O4 
O5 
Hydrogen bond 
Hydrogen bond 
2.9 
3.0 
Asp12
4 
 
O 
 
O8 
 
Hydrogen bond 3.5 
 
Thr12
6 
 
OG1 
 
O1 
 
Hydrogen bond 3.3 
 
Arg13
2 
NE O4´ Hydrogen bond 2.2 
Arg98  Phenol moiety Cation-π interaction  5 
Thr48 
Asp12
4 
OG1 
OD1 
HOH38 
HOH38 
HOH38 
 
 
O7 
 
 
Water mediated 
interaction 
3.3 
3.2 
2.3 
Thr12
6 
Tyr193 
OG1 
OH 
HOH97 
HOH97 
HOH97 
 
 
O1 
 
 
Water mediated 
interaction 
3.5 
2.2 
2.6 
     
Protein residue Water Inhibitor 
Y1 
Type of interaction Distance 
(Å) 
Arg75 NH1  O4´ Hydrogen bond 3.5 
Arg98 NE  O8 Hydrogen bond 3.2 
Thr12
6 
OG1  O4 Hydrogen bond 3.5 
Arg98   Chromone 
moiety 
Cation-π interaction 4 
Arg18
9 
  Phenol moiety Cation-π interaction 3.5 
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group on Tyr424 is tilted toward N4A due to the repositioning of water molecules near Tyr424 
upon N4A binding. These local conformational changes in the F-6-P pocket affect the mobile 
ATP loop, especially a turn (residues 168-180), which flips into the F-6-P pocket, a displacement 
of over 2 Å (data not shown). 
Y1 and YZ9 from the exploration of 4A scaffold 
 YN1 To increase the inhibition potency of N4A, firstly, we performed a similarity 
search using N4A as a template and with a defined Tanimoto coefficient ≥0.9 (Perez 2005). The 
selected molecules from the entire NCI Database were evaluated via computational docking 
(Gohlke et al. 2000) and, as a result, ZINC06093399 (YN1) was predicted to have significantly 
improved potency as a PFKFB3 inhibitor. YN1, purchased from CHESS GmbH, was tested for 
its inhibition potency and kinetic properties and demonstrated a 5-fold increase in PFKFB3 
inhibition compared to N4A (Table 2.1). 
In order to determine the molecular basis for the increased inhibition potency of YN1, the 
crystal structure of the PFKFB3 in complex with YN1 was also determined but at the modest 
resolution of 3.3 Å. Because of this resolution limit, the structure refinement was performed 
using only rigid body and B-group refinement, taking the whole protein structure of the N4A 
complex as a rigid body. Similar to N4A, YN1 binds to the Fru-6-P binding pocket as clearly 
shown in an omit |Fo|−|Fc| electron density maps (Figure 6E). In addition, like N4A, YN1 
interacts with PFKFB3 by occupying the Fru-6-P pocket.  However, the electron density for YN1 
is better modeled by flipping YN1 180° in respect to its short axis, compared to the orientation of 
N4A, resulting in the phenol moiety of YN1 being positioned towards the site occupied by the 
fructose moiety of Fru-6-P rather than the site of the phosphate of Fru-6-P. This orientation may 
be a consequence of the substitution of benzenediol for benzenetetrol in the chromone moiety of 
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the two inhibitors. The additional hydroxyl groups on the chromone moiety of N4A perhaps 
cannot be accommodated at the binding site for the 6-phosphate moiety of Fru-6-P. However, 
YN1 with a loss of two hydroxyl groups in the same chromone moiety is able to bind to the site 
in a direction opposite that of N4A. Then, the chromone moiety of YN1 is inserted between 
Val70 and Phe87 gaining hydrophobic interactions and a Cation-π interaction with Arg98, while 
its phenol moiety gains a Cation-π interaction with Arg189 and a hydrogen bond with Arg75 
(Table 2.2). Water mediated interactions, similar to those observed in the N4A complex, very 
likely contribute to the YN1 interaction, although the resolution limit did not allow for the 
modeling of water in the YN1 complex.  
Certainly, our observations regarding YN1 require supporting evidence from high 
resolution X-ray data. Nevertheless, because only the position of YN1 was refined inside the 
N4A binding pocket as a rigid body, this new binding mode observed for YN1 is significant. 
Comparison of the binding modes of N4A and YN1 suggested that the Fru-6-P pocket of 
PFKFB3, with a number of Arg residues present, is surprisingly generous to the binding of 
compounds with hydrophobic rings. It is likely that the pocket takes advantage of Cation-π 
interactions as seen in other structures (Beene et al. 2002) and water-mediated hydrogen bonds. 
The higher potency of YN1 compared to N4A and the apparent difference in binding modes 
between the two compounds, taken together, suggest that compounds containing a chromone 
moiety with fewer hydroxyl groups will be more potent than either N4A or YN1. 
YZ9 Using a strategy similar to that used to find YN1, we identified YZ9.  Using the 
same biological test routine, we determined that YZ9 inhibited PFKFB3 with an IC50 of 0.183µM, 
and acted as a competitive inhibitor against Fru-6-P with a Ki of 0.094 µM (Table 2.1). YZ9 also 
inhibited the cell growth with a GI50 of 2.7 µM. Further characterization of YZ9 is on-going.   
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Discussion 
Suppression of anaerobic glycolysis has been suggested as a promising strategy for the 
development of chemotherapeutic agents for cancer, because tumor cells exhibit an abnormally 
high glycolytic rate even in the presence of oxygen (Pelicano et al. 2006; Tennant et al. 2010; Xu 
et al. 2005). The rate of glycolysis is regulated by the cellular concentration of Fru-2,6-P2, a 
potent stimulator of glycolysis(El-Maghrabi et al. 2001; Pilkis et al. 1995; Van Schaftingen et al. 
1981b). Recent studies invariably show that Fru-2,6-P2 production is increased in transformed 
cell lines due to the expression of PFKFB3, the hypoxia-inducible isoform of the 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatases, that catalyzes the synthesis of Fru-2,6-P2 
at least ten times greater rate than other isoforms (Atsumi et al. 2002; Calvo et al. 2006; Hue and 
Rousseau 1993; O. Minchenko et al. 2003; Telang et al. 2006). Accordingly, it has been 
hypothesized that inhibition of PFKFB3 would deprive tumor cells of energy sources necessary 
for proliferation and growth (Calvo et al. 2006; Tennant et al. 2010).  
 In this report, we were able to introduce a potent competitive inhibitor of PFKFB3, N4A 
with an IC50 of 2.97µM. The inhibitor also shows a stronger effect on PFKFB3 than on other 
PFKFB isoforms. Despite high homology between PFKFB isoforms, the inhibitor has much 
higher specificity for PFKFB3 than we thought. As a result of proper targeting, the PFKFB3 
inhibitor reduced the Fru-2,6-P2 level and glycolytic rate in cell, ultimately, leading to tumor 
growth inhibition and massive cell death. The cell death induced by the inhibitor involves both 
apoptosis and necrosis. Our observation is coincident with previous reports that depletion of 
cellular energy tends to cause necrotic cell death, because apoptosis is an energy requiring 
process (McConkey 1998; Richter et al. 1996; Xu et al. 2005). Supporting this idea, we found 
apoptotic cell death was primarily observed at a relatively low inhibitor concentration (25 µM), 
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which would produce only moderate energy depletion. On the other hand, higher concentration 
of inhibitors (50 µM) significantly increased both necrosis and apoptosis, leading to an 
insufficient energy state where the apoptotic process is not favored.  
Although N4A and YN1 show comparatively selective PFKFB3 inhibition between the 
PFKFB isoforms, the anti-proliferative effect of the inhibitors on cancer cells cannot be solely 
ascribed to the inhibition of PFKFB3 kinase activity. However, the development of N4A and 
YN1 is a first step toward the goal to obtain specific PFKFB3 inhibitors possessing high 
selectivity and low general toxicity.  
Determination of protein structures in complex with an inhibitor is necessary to obtain 
mechanisms for inhibitor recognition at the molecular level and to provide an opportunity to 
identify alternative molecules with higher potency (Blundell et al. 2002; Kuntz 1992). 
Understanding the molecular basis for interactions between a potential drug molecule and its 
target protein is a critical step in successful drug development (Blundell et al. 2002). We were 
able to determine the first molecular structure of PFKFB3 in complex with an inhibitor, and then 
use this structural data to improve potency of the inhibitor. The crystal structures of PFKFB3 in 
complex with N4A revealed information on inhibitor binding at the molecular level. The crystal 
structure with YN1 provided an insight into alternative bindings of similar compounds, despite 
the moderate resolution. The two together provided the blue print of new compounds and rational 
guidelines for design of novel PFKFB3 inhibitors. Although YN1 is a derivative of the lead 
compound N4A and the binding modes of the two inhibitors are in approximately the same plane, 
it appears, even at the modest resolution of the YN1 complex, that the interactions of these two 
compounds with PFKFB3 are quite different. The difference of orientations within the same Fru-
6-P plane is likely the consequence of YN1 having a less bulky chromone moiety (two fewer 
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hydroxyl groups compared to N4A). The new binding mode observed for YN1 results in new 
hydrophobic interactions and the addition of Cation-π interactions, which together compensate 
for the loss of hydroxyl groups, which participated in hydrogen bond in the N4A complex, and 
appear to support the higher inhibitory activity of YN1. It is noteworthy that our inhibitors with 
no negatively charged group efficiently target the Fru-6-P pocket, which is populated with 
positively charged residues. The accompanied energy penalty for such bindings is likely to be 
paid by increases in the Cation-π interactions. This speculation was tested with the third 
compound YZ9, which showed the inhibition potency increased by an order of magnitude, 
although detailed characterizations including a structural analysis have yet to be performed. 
Our data suggested the approach taken in this report will enable the rational design of 
PFKFB3 inhibitors, which will have a higher specificity by targeting the Fru-6-P site instead of 
targeting the ATP site since the ATP site fold is shared by thousands of other kinases (Davies et al. 
2000; Hanks et al. 1988). This report provides a framework for the rational development of the 
PFKFB3 inhibitors as new cancer therapeutics. 
Materials and Methods 
2-kase assay and kinetic analysis 
 To determine steady-state initial reaction rates, the 2-Kase reactions were performed first 
and the Fru-2,6-P2 produced was measured by a conventional enzyme-coupled kinetics assay as 
described previously(Kim et al. 2007; Van Schaftingen et al. 1982). Initial rates of decrease in 
absorbance (Abs) at 340 nm were corrected with the rate of the control reaction in which no Fru-
2,6-P2 was present. Negative controls were carried out in the absence of enzyme and positive 
controls indicate the reaction in the presence of enzyme without inhibitor compounds. The 
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percentage of Inhibitory activity was calculated according to the formula: % inhibition = 
100 [1- (Abs negativecontrol-Abs compound) /(Abs negativecontrol -Abs positivecontrol)]. IC50 values were 
determined in quadruplicate. For the kinetic studies, concentrations of one of substrate and 
inhibitor were varied and decrease in absorbance at 340 nm was measured. The inhibition 
patterns were analyzed using the program written by Cleland, in which Ki is the dissociation 
constants for the inhibitor from enzyme-inhibitor complex(Cleland 1979). For Selectivity studies, 
the 2-Kase assays were performed first and the F-2,6-P2 produced was measured by an enzyme 
coupled kinetics assay as described above.  The His6-tagged PFKFB isoforms, PFKFB1, 
PFKFB2, and PFKFB4 were expressed in Escherichia coli C41(DE3) and purified using Ni-NTA 
affinity columns. 
Similarity Search 
 Similarity searches, using N4A or YN1 as a template, were performed using the NCI 
Enhanced Web Browser (http://129.43.27.140/ncidb2/) with a defined Tanimoto coefficient ≥0.9 
(Perez 2005). The entire Open NCI Database was used using Tanimoto index and the selected 
compounds were consequently evaluated through docking.  Docking was performed on the 
structure of the PFKFB3•ADP•F6P complex (PDB code: 2AXN), using FlexX, after stripping 
the ligands (Gohlke et al. 2000; Kim et al. 2007).   The docking calculations were performed 
with an active-site encompassing a sphere of 15 Å around the reference structure position in the 
PDB file. The high rank compounds were purchased from CHESS GmbH (Germany) or from 
other suppliers.   
Preparation and crystallization of PFKFB3 
Preparation of the protein sample and its crystallization was performed as described(Kim 
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et al. 2006). The 6XHis-tagged human PFKFB3 was expressed in Escherichia coli BL21(DE3) 
pLysS and purified using Ni-NTA affinity columns and, subsequently, Mono Q anion-exchange 
chromatography. The resulting pure protein was kept, after concentrating to 8 mg ml- 1 protein, in 
20 mM Tris•HCl (pH 8.0), 10 mM NaPi, 0.05 mM EDTA, 5 mM β-mercaptoethanol, 5% 
glycerol, 0.2 mM Fru-6-P. Crystals were prepared by the sitting-drop, vapor-diffusion method 
with a 1:1 (v/v) mixture of the protein sample with a reservoir solution of 50 mM HEPES pH 7, 
7–20% DMSO, 0.2–1.5mM of inhibitors, and 7% (w/v) polyethylene glycol 4000. Crystals with 
a size of 0.2 mm × 0.1 mm × 0.2 mm grew in two to three weeks. 
Cell culture 
HeLa and T47D cell lines were cultured in a 10% CO2 humidified atmosphere at 37 °C as 
exponentially growing monolayers in Dulbecco’s modified Eagle’s medium (DMEM) with 
glutamax (Invitrogen), supplemented with 10% fetal calf serum (Invitrogen) and 
penicillin/streptomycin (100 U/ml and 100 µg/ml). The human cervical carcinoma cell line, 
HeLa, was kindly provided by Dr. J. Kim (Louisiana State University) and the human breast 
carcinoma cell line, T47D, was obtained from the American Type Culture Collection (Manassas, 
VA). 
Metabolite determination 
HeLa cells were plated at a density of 2.5X105 in a 6-well plate in DMEM containing 
10% FCS. The media were replaced with fresh DMEM containing either vehicle (dimethyl 
sulfoxide) or 25µM of inhibitor the following day.  After 0, 4,8,12,24, or 48 hours of incubation 
with each inhibitor, media samples were collected for measuring the lactate secretion levels 
using a lactate oxidase-based assay kit (Sigma-Aldrich) and the lactate concentration was 
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normalized to the total cellular protein concentration. The Fru-2,6-P2  level was determined with 
collected cells at times of 0, 4,8,12,24, or 48 hours after the treatment, using the method 
described previously(Van Schaftingen et al. 1982). 
Cell Proliferation/Survival Assays 
Cell growth inhibition was determined by an XTT-based in-vitro toxicology assay 
(Sigma-Aldrich) or trypan blue staining. Cells were plated at a density of 3.5X104 per well in a 
24-well plate in DMEM containing 10% FCS. These cells were allowed to attach for 24 hours, 
and the media were replaced with fresh media containing either vehicle (dimethyl sulfoxide) or 
appropriate concentrations of test compounds. After 36 hours of incubation with either vehicle or 
compounds, cells were trypsinized and cell viability was determined by the trypan blue exclusion 
assay using a hemacytometer. For the XTT assay, cells were seeded into 96-well cell culture 
plates at a density of 0.6X104 per well. After  the appropriate treatment described above, cells 
were incubated with 0.1 mg/ml of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) for 4 hours and then cell number was 
determined by the absorbance at 470 nm, which is proportional to the number of cells that 
remained attached to the plate. GI50s were calculated as the inhibitor concentration needed for 
50% of vehicle-treated cell growth. The appearance of apoptotic or necrotic cells was determined 
by flow cytometric analysis of cells double stained with Annexin V-FITC and propidium iodide 
(PI)(van Engeland et al. 1998) . Apoptotic and necrotic cells were distinguished on the basis of 
double-labeling for Annexin V-FITC (Sigma-Aldrich) and PI, a membrane-impermeable DNA 
stain. Floating and freshly trypsinized cells were pooled, washed twice in binding buffer, and 
processed following manufacturer’s instructions. The fluorescence of samples were analyzed by 
flow cytometry (FACSCalibur®, Becton Dickinson Immunocytometry, San Jose, CA) using the 
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CellQuest (BD Bioscience, Immunocytometry Systems, San Jose, CA, USA) software. 
For HeLa cell colony formation was determined by soft agar assay. Cells (2X103) were 
mixed in DMEM medium containing 0.35% agarose and varying concentrations of N4A or YN1. 
Then the cell mixture was added on a layer of 0.6% concentration of bottom agar in 24 well plate 
and allowed to grow for three weeks at 37°Cunder 5% CO2. Fresh medium containing the 
inhibitors or vehicle (DMSO) was changed every four days. Colonies of 50 cells or more were 
counted after three weeks. The experiments were repeated at least five times. 
Diffraction data collection and processing 
Crystals were soaked with cryoprotectant solutions for 0.5 to 2 hours before cryogenic 
data collections. Depending on the experimental aims, cryoprotectant solutions (a crystallization 
reservoir solution enriched with 30% glycerol) were enriched with 0.3mM of inhibitor. A soaked 
crystal was flash-frozen at 100 K using an Oxford cryo-device and kept at the same temperature 
during data collections. The diffraction data were collected at The Northeastern Collaborative 
Access Team (NE-CAT) Beamline at the Advanced Photon Source, Argonne National 
Laboratory, Argonne, IL. The X-ray source wavelength was 0.9792 Å. The data recorded on a 
ADSC Q315 detector were integrated, merged, and scaled using XDS(Kabsch 2010). Statistics 
of the diffraction data and structure refinement are summarized in Table 2.3. The crystals belong 
to P6522 space group with similar cell dimensions. 
Structure determination and refinement 
The reduced data were formatted for the program suites of CCP4(1994)  and 10% of the 
data were marked for free R-factor measurements in subsequent structure refinements. The 
search model was built from the coordinates of the PFKFB3•Fru-6-P•EDTA complex structure 
(PDB accession code 2AXN)(Kim et al. 2007) by stripping all the included ligand and solvent 
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molecules to determine the N4A complex structures of PFKFB3. The initial model was 
determined using REFMAC within the CCP4 suit and processed through iterated cycles of 
manual model rebuilding and validation using the program COOT (1994). Binding of the ligands 
was confirmed, referring to the |Fo|–|Fc| omit maps that were generated, when Rcrys/Rfree reached 
0.23/0.29 or below. Referring to these maps, Fru-6-P, N4A or YN1 was incorporated into the 
corresponding complex models. As summarized in Table 2.3, the final model of the 
PFKFB3•Fru-6-P•N4A complex has Rcrys/Rfree of 0.215/0.262 using a total of 3881 scatterers, 
including solvent molecules, against all available 26,883 reflections in the resolution range of 
61.6–2.4 Å.  The structure contains a total of 443 amino acid residues of the full-length protein 
of 520 residues. As in the PFKFB3•ADP•EDTA complex, the C terminus (residues 446–520) is 
mostly disordered. The PFKFB3•Fru-6-P•YN1 complex was built from N4A complex through 
only rigid body and B-group refinement because of resolution limit, resulting with  Rfree/Rcrys of 
0.243/0.250 using a total of 3700 scatterers against all available 12,140 reflections in the 
resolution range of 89.0–3.3 Å. The structure contains a total of 448 amino acid residues of the 
full length protein of 520 residues. In the both structures, more than 89% of the residues are in 
the most favored region, 9.5% in the additional region, and the rest in the generously allowed 
region in the Ramachandran plots. The structure refinement statistics are summarized in Table 
2.3. 
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Table 2.3 Statistics of reflection data and structure refinements  
 
PFKFB3·Fru-6-P·N4A PFKFB3·Fru-6-P·YN1 
Space group P6522 P6522 
Unit cell dimensions   
a = b (Å) 101.70 102.78 
c (Å) 258.61 260.10 
Resolution range (Å) 61.6-2.4 50.4-3.3 
No. reflections used  26,883 20,476 
Completeness (%) 100.00 88.96 
Redundancy 7.2 (2.6) 9.5 (2.2) 
I/σ (I) 10.03 6.2 
Rsym 0.055 0.069 
Rcrys 0.215                        0.243 
Rfree 0.262                       0.250 
No. amino acids 443 441 
No. protein atoms 3881 3637 
No. hetero atoms 52 40 
No. water molecules 192 - 
r.m.s.d. from ideal   
Bond lengths (Å) 0.021 - 
Bond angles (deg.) 2.016 - 
Dihedral angles (deg.) 20.9 - 
Mean Bfactor   
Protein atoms (Å2) 35.53 90.93 
Hetero atoms (Å2)  48.23 106.73 
Water atoms (Å2) 43.08 - 
Rsym = ∑h(∑j|Ih,j–<Ih>|/∑Ih,j), where h = set of Miller indices, j = set of observations of 
reflection h, and <Ih>=the mean intensity. Rcrys = ∑h||Fo,h|–|Fc,h||/∑h|Fo,h|. Rfree was 
calculated using 10% of the complete data set excluded from refinement. The numbers in 
parentheses represent values from the highest resolution shell. 
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CHAPTER 3: PFKFB3 REGULATES OXIDATIVE STRESS HOMEOSTASIS 
VIA ITS S-GLUTATHIOYLATIO I CACER 
Introduction 
Control of cellular oxidative stress is critical for cell proliferation and survival (Finkel 
and Holbrook 2000; Martindale and Holbrook 2002). Moderate levels of reactive oxygen species 
(ROS) can support cell proliferation, whereas excessive levels of ROS cause detrimental 
oxidative stress that damage cellular components and lead to cell death (Valko et al. 2004).  
Cancer cells exhibit higher levels of ROS compared to normal cells (Kasai 1997; Klaunig and 
Kamendulis 2004; Valko et al. 2006) because tumorigenic conditions, including aberrant 
metabolism, hypoxia, inflammation and mitochondrial dysfunction, constantly generate 
ROS(Dreher and Junod 1996; Klaunig and Kamendulis 2004; Toyokuni et al. 1995).  Therefore, 
cancer cells are challenged in regulating ROS not only to avoid the toxic effects of excessive 
ROS, but to promote ROS-induced proliferation and oncogenic mutations.  However, the 
underlying mechanism for tight ROS control in cancer cells remains unclear.   
 Reduced glutathione (GSH) is the most abundant intracellular antioxidant that scavenges 
ROS at the expense of reduced nicotinamide adenine dinucleotide phosphate (NADPH), which is 
generated in the initial steps of the pentose phosphate pathway (PPP) (Schafer and Buettner 
2001).  Glutathione can cause protein S-glutathionylation, the formation of a disulfide bridge 
between the thiol group of glutathione and an accessible free thiol on proteins (Dalle-Donne et al. 
2007; Klatt and Lamas 2000).   S-glutathionylation is reversible and known to regulate signal 
transduction as well as localization and functionality of redox-sensitive proteins (Dalle-Donne et 
al. 2009; Gallogly and Mieyal 2007). 
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Among a family of bifunctional enzymes, PFKFB1–4, each of which controls glycolytic 
flux by regulating the levels of key glycolytic stimulator, fructose-2,6-bisphosphate (Fru-2,6-P2) 
in a tissue-specific manner, PFKFB3 is the predominant isoform in cancers (Rider et al. 2004). 
Its unique characteristics such as hypoxic regulation of protein expression, mitogen and 
oncogene-dependent upregulation and its predominant 2-Kase activity suggest that PFKFB3 is 
strongly linked to markedly increased glycolysis within cancer cells (Atsumi et al. 2002; Calvo 
et al. 2006; Rider et al. 2004; Telang et al. 2006). 
We observed that excessive ROS causes S-glutathionylation of PFKFB3, causing a 
severe decrease in its catalytic activity for the synthesis of Fructose-2,6-bisphosphate (Fru-2,6-
P2), the glycolysis rate-regulating activator.  In view that glycolysis and the PPP are two 
interconnected metabolic pathways, we hypothesized that S-glutathionylation of PFKFB3 
reduces glycolysis and stimulates PPP to decrease the cellular oxidative stress.   As such, the 
present study was aimed to investigate the structural basis and cellular mechanism for PFKFB3 
S-glutathionylation. We also determined the functional consequences of PFKFB3 S-
glutathionylation at the cellular level. 
Results 
Identification of S-glutathionylation of PFKFB3 
We observed that oxidized glutathione (GSSG) selectively glutathionylates PFKFB3 
among the four isoforms in a reversible manner (Figure 3.1). When all four purified PFKFB 
isoforms were treated with a physiological level (3mM) of total glutathione at 1:1 molar ratio of 
GSH to GSSG, only PFKFB3 was S-glutathionylated (Figure 3.1D). To obtain the molecular 
basis of S-glutathionylation of PFKFB3, we crystallized glutathionylated PFKFB3 and 
determined the structure of the complex to 2.2Å resolution by a method of molecular 
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replacement using the first PFKFB3 structure (PDB code: 2AXN) as a search model (Kim et al. 
2007).  
 
Figure 3.1 An isoform-specific S-glutathionylation of PFKFB3. (A) Structure of PFKFB3 
showing site of S-glutathionylation within the kinase domain (yellow). S-glutathionylation 
(purple) on C206 is shown with an |Fo|−|Fc| omit map at a 2.5σ level. (B) Glutathionylated 
Cys206 is located on the kinase surface surrounded by basic residues, Arg131, His135, and 
Lys205. The Fru-6-P and ADP are shown in dark gray for comparison. (C) Amino acid sequence 
alignment among human PFKFB isoforms, PFKFB1, PFKFB2, Two splicing variants of 
PFKFB3, and PFKFB4 (the ClustalW program). Fully conserved, conserved, and similar 
residues at each position are symbolized by an asterisk (*), colon (:), and dot (.), respectively. 
Purple shading (^) shows conserved cysteine residues and yellow shading (+) shows cancer form 
specific S-glutathionylated cysteine residue. (D) Immunoblotting of protein S-glutathionylation 
after 25min incubation with 3mM 1:1 molar ratio of GSH to GSSG. Bottom: SDS-PAGE 
separated input PFKFB isoforms (1-4) were visualized by Coomassie blue staining. 
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Its crystal structure revealed that this S-glutathionylation is made on a PFKFB3-unique 
cysteine residue, Cys206 (Figure 3.1A, C, and Table 3.1). This residue is located close to the 
Fru-6-P binding pocket of the kinase domain, suggesting an effect on the kinase activity (Figure 
3.1B). The neighboring basic residues, Arg131, His135, and Lys205, are likely to facilitate 
deprotonation of Cys206 and attraction of the negatively charged glutathione to the site. 
Effects of reversible S-glutathionylation of PFKFB3 on Enzymatic Activity 
Treatment of GSSG induces S-glutathionylation of human PFKFB3 in a dose-dependent 
manner (Figure 3.2A) and, as suggested by the structural analysis, greatly decreased the kinase 
activity (Figure 3.2B). The full kinase activity was recovered upon the treatment with reducing 
agents. The addition of a bulky negatively charged glutathione to near the Fru-6-P binding 
pocket could prevent Fru-6-P entry because of repulsion. The phosphatase activity of PFKFB3 
remained essentially unchanged upon S-glutathionylation (data not shown). The significance of 
modification at Cys206 was tested by mutagenesis to Alanine (C206A). Whereas wild-type 
(WT) is glutathionylated with a roughly 80% loss of kinase activity at 1:1 molar ratio of GSH to 
GSSG, C206A abrogated S-glutathionylation with no loss of kinase activity under the same 
condition (Figure 3.2C, D). Thus, Cys206 is critical for glutathionylation-induced kinase 
inactivation. 
Glucose metabolism through the PPP, which is directly interconnected with the 
glycolysis, provides NADPH to protect cells from ROS by maintaining the GSH level (Circu and 
Aw 2010; Cosentino et al. 2011). We hypothesized that the inactivation of PFKFB3 kinase 
decreases glycolysis via decreased Fru-2,6-P2 and reroutes the glucose metabolic flux to PPP as 
alternative pathway to counteract ROS.  
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Figure 3.2 S-glutathionylation inhibits PFKFB3 kinase activity, redirecting metabolic 
fluxes from glycolysis to the PPP in vitro. 
(A) Immunoblotting of a dose-dependent PFKFB3 S-glutathionylation after 25min treatment 
with varying molar ratios of GSH to GSSG. (B) Kinase activity of S-glutathionylated PFKFB3 
after 25min pre-treatment with varied molar ratio of GSH to GSSG. Data represent percentage of 
control (without preincubation) (n=3experiments). (C) Immunoblotting of S-glutathionylation of 
purified WT-PFKFB3 and C206A after pre-treatment with 3mM 1:1 molar ratio of GSH to 
GSSG. (D) Kinase activity of C206A under ROS condition. (E) Diagram showing a subset of 
glycolysis (left) and the interconnected PPP, which is controlled by S-glutathionylation of 
PFKFB3 (right). Solid /bold lines represent direct, one-step biochemical reactions, and indirect, 
multi-step reactions are represented as dotted lines. Inhibition and activation of enzymatic steps 
are indicated by solid/plain lines. G-6-P, glucose-6-phosphate; Ribul-5-P, ribulose-5-phosphate; 
Fru-6-P, fructose -6-phosphate; Fru-1,6-P2, fructose-1,6-bisphosphate; Fru-2,6-P2, fructose-2,6-
bisphosphate; PFKFB3-SSG, S-glutathionylated PFKFB3; PFKFB3-SH, unglutathionylated 
PFKFB3. (F) In vitro enzymatic assay of linear metabolic pathway for the interplay of glycolysis 
and the PPP in response to PFKFB3 S-glutathionylation. Upon S-glutathionylation of PFKFB3, 
the formation of Fru-2,6-P2 and NADPH was measured as representative products of each branch 
of our combining metabolic pathway, part of glycolysis and the PPP. 
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 To investigate this hypothesis, we designed an in vitro assay of a linear metabolic pathway for 
the interplay between glycolysis and PPP in response to S-glutathionylation-induced PFKFB3 
kinase inactivation. The first step of PPP, the rate-limiting generation of D-6-phosphoglucono-δ-
lactone from glucose-6-phosphate (G-6-P), and steps in glycolysis, from G-6-P to Fru-6-P and to 
Fru-2,6-P2 (Figure 3.2E), are targeted and included in the assay system. Because the level of Fru-
2,6-P2 is directly affected by PFKFB3 inactivation and is a key regulatory factor for 6-
phosphofructo-1-kinase (PFK), the rate-limiting enzyme of glycolysis(El-Maghrabi et al. 2001; 
Van Schaftingen et al. 1981b), we measuredFru-2,6-P2 levels as the indicator of the glycolytic 
flux. The PPP flux was determined by measuring the level of NADPH formation. The GSSG 
treatment of PFKFB3 decreased glycolysis flux by lowering Fru-2,6-P2 levels but increased the 
PPP flux in a dose-dependent manner (Figure 3.2F).Thus, these experiments demonstrated that 
the S-glutathionylation of PFKFB3 reroutes the metabolic flux from glycolysis to the PPP. 
PFKFB3 Undergoes S-glutathionylation under in Vivo Conditions Associated with Increased 
Cellular Oxidative Stress 
Next, the same hypothesis was tested in a near in-vivo situation using the cultured HeLa 
cells. To create an oxidized environment, we exogenously applied the cells with hydrogen 
peroxide (H2O2) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), which is known to induce 
accumulation of cellular GSSG by inhibiting glutathione reductase (Forman 2007). Both H2O2 
and BCNU enhanced the generation of oxidative stress in HeLa cells. A moderate increase in 
ROS was observed at relatively low concentrations of H2O2 or BCNU (30µM and 10µM, 
respectively), whereas levels of ROS become excessively high at higher concentrations (100µM 
and 80 µM, respectively) (Figure 3.3A). A pull-down assay with cell permeable biotinylated 
GSH ethyl ester (Bio-GEE) followed by immunoblotting confirmed that high ROS conditions, 
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H2O2 (100 µM) or BCNU (80µM), lead to S-glutathionylation of PFKFB3 in HeLa and 293T 
cells expressing PFKFB3 (Figure 3.3B, D). Under the same conditions, H2O2-induced S-
glutathionylation of endogenous PFKFB3 in HeLa cells was detected, strongly suggesting 
PFKFB3 S-glutathionylation as an oxidative stress response in vivo (Figure 3.3C).  
 
 
Figure 3.3 Oxidative stress induced PFKFB3 S-glutathionylation in cancer cells. 
(A) ROS levels in HeLa cells after H2O2 and BCNU treatment. Error bars denote SEM. T-test 
(*P < 0.05, **P < 0.01) used for all figures. Detection of S-glutathionylation of PFKFB3 after 
incubation with 100µM H2O2 (B) or the indicated doses of BCNU (D, upper two lows) in HeLa 
and 293T cells expressing PFKFB3. Cells were incubated with or without 1.5mM Bio-GEE and 
H2O2, and then biotin-GSS-protein conjugates were precipitated using streptavidin-agarose. 
Immunoblotting shows PFKFB3 levels before (input, bottom) and after precipitation (upper) 
(60ug of total protein per lane). Detection of S-glutathionylation of endogenous PFKFB3 in 
HeLa cells after incubation with H2O2 (C) or BCNU (D, Bottom two rows) using Bio-GEE. 
Immunoblotting shows PFKFB3 levels before (input, bottom) and after precipitation (upper).  
 
 
 65 
 
Functional Consequences of PFKFB3 S-glutathionylation on Metabolic Alteration and ROS 
Regulation 
 Because glycolysis and the PPP are interconnected, it is likely that S-glutathionylation of 
PFKFB3 reduces glycolysis thereby stimulating the PPP to decrease the cellular oxidative stress. 
Overexpression of WT-PFKFB3 increased the release of lactate and intracellularFru-2,6-P2 
concentrations in HeLa cells, but H2O2 (or BCNU)-induced oxidative stress abolished such 
responses (Figure 3.4A, B). However, overexpression of C206A displayed a consistent increase 
in lactate and Fru-2,6-P2 levels in the presence or absence of H2O2 or BCNU, compared with 
empty vector control. Thus, acute oxidative stress triggers a ROS-dependent S-glutathionylation 
of PFKFB3, resulting in a decrease in glycolysis. We then tested whether the decreased 
glycolytic flux caused by PFKFB3 S-glutathionylation would shift the carbohydrate flux to the 
PPP. ROS induced a significant increase in levels of the PPP metabolites, Ribul-5P and Xyl-5P, 
in HeLa cells expressing WT, when compared with control cells expressing an empty vector 
(Figure 3.4C). The elevated PPP flux was dampened to the levels of control cells by introducing 
overexpression of C206A. These results altogether suggest that PFKFB3 S-glutathionylation 
redirects the carbohydrate flux from glycolysis to the PPP thereby regulating oxidative stress in 
cancer cells.  
 Glucose metabolism through the PPP provides NADPH to maintain glutathione in the 
reduced state and proper ROS level (Circu and Aw 2010; Cosentino et al. 2011; Schafer and 
Buettner 2001). To determine the effect of ROS-induced S-glutathionylation of PFKFB3 on the 
cellular oxidative stress, the GSSG-to-GSH ratio and levels of NADPH and ROS were measured 
using cells expressing WT and C206A. A slight decrease in NADPH levels accompanied with an 
increased GSSG-to-GSH ratio was found in cells expressing WT andC206A. This might be a 
result of increases in glycolysis caused by the high kinase activity of PFKFB3. 
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Figure 3.4 PFKFB3 S-glutathionylation redirects the carbohydrate flux from glycolysis to 
the PPP, protecting cancer cells from ROS-induced cell death. Intracellular Fru-2,6-P2 
concentration (A), the secreted lactate levels (B), cellular concentration of Ribul-5P and Xyl-5P 
(C), NADPH (D), and GSH/GSSG ratio (E) after oxidant treatments to induce PFKFB3 S-
glutathionylation using HeLa cells transiently expressing empty vector pcDNA3.1 (Con), 
expression plasmids for WT- or C206A-PFKFB3.  Absolute values were normalized to the total 
protein concentration and changes in metabolite levels are expressed as a percent of control 
(without oxidant treatment).T-test (*P < 0.05, **P < 0.01, ***P< 0.001, $P<0.06 (marginally 
significant); N.S., not significant) used for all figures. (F) Intracellular ROS levels for empty 
vector (Con) and WT-PFKFB3 expression after H2O2treatment. The results are expressed as the 
mean DCF-fluorescence. Cell survival after 30hours treatment with H2O2 (G) or BCNU (H) 
using HeLa cells expressing empty vector pcDNA3.1 (Con), expression plasmids for WT- or 
C206A-PFKFB3. 
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Treatment with oxidizing agents moderately increased intracellular NADPH concentrations in 
cells expressing WT, but not in cells expressing C206A (Figure 3.4D). As expected, H2O2 or 
BCNU treatment moderately enhanced the GSSG-to-GSH ratio in cells expressing WT, while 
the treatment excessively increased GSSG levels in cells expressing C206A (Figure 3.4E). This 
indicates that the PFKFB3 S-glutathionylation is required for the PPP activation to generate 
reducing equivalents under oxidative conditions. When the cells were treated with increasing 
concentrations of H2O2, control cells expressing an empty vector showed consistently increased 
ROS levels, whereas cells expressing WT demonstrated evident ROS regulation by which ROS 
levels start to decrease after exceeding a certain limit of ROS stress (Figure 3.4F). 
 Together, these results strongly suggest that PFKFB3 maintains ROS below the threshold 
toxic levels, but at moderately elevated levels to promote proliferation, oncogenic mutations, and 
stress responses. At low levels of ROS, PFKFB3 stimulates glycolysis, resulting in increased 
rates of ROS production. However, at high levels, ROS induces PFKFB3 S-glutathionylation, 
elevating the PPP flux for ROS detoxification. 
Glutathionylation of PFKFB3 Supports Cancer Cell Survival 
To further determine whether this mechanism is relevant to cancer cell survival under 
oxidative stress, we employed cell viability assay. In response to ROS inducing treatments, 
increased cell survival was observed by introducing overexpression of WT-PFKFB3, but not by 
C206A overexpression (Figure 3.4G, H), suggesting that S-glutathionylation of PFKFB3 in 
cancer cells involves cellular resistance against ROS-associated cell death. The results reveal 
how glucose metabolism and cellular ROS levels can be efficiently regulated by the S-
glutathionylation of PFKFB3 in order to protect cancer cells against oxidative stress. 
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Discussion 
In addition to its known harmful effect, recent evidence suggests that ROS also functions 
as intracellular messengers to modulate the activities of various proteins in signaling pathways 
that are involved in stress response and cell survival (Droge 2002; Menon and Goswami 2007; 
Terada 2006).  Recent reports have shown that adaptation to ROS stress causes malignant 
transformation, metastasis, and drug resistance in cancer (Fruehauf and Meyskens 2007; 
Toyokuni et al. 1995; Trachootham et al. 2009). In order to develop a promising strategy for 
cancer therapy and to overcome drug resistance associated with ROS adaptation, it is necessary 
to understand ROS regulation in cancer cells. PFKFB3 seems to serve as a metabolic master 
switch in cancers that senses and controls ROS stress by stimulating the PPP flux at the high 
ROS levels through S-glutathionylation, enhancing NADPH generation for ROS detoxification 
to reduce oxidative stress. PFKFB3 S-glutathionylation can be reversed at low ROS levels to 
recover the PFKFB3 activity, leading to enhanced rates of glycolysis with increased ROS 
production. This mechanism allows cancer cells to maintain moderate ROS levels below a toxic 
threshold yet within a range that can support tumor progression. Moreover, ROS-induced S-
glutathionylation of PFKFB3 acts as a key mechanism to regulate metabolic pathways in order to 
facilitate the incorporation of nutrients into the biomass that enables cell growth and proliferation 
in cancer cell since the intermediates of the PPP are necessary precursors for nucleotide and 
phospholipid synthesis (Vander Heiden et al. 2009). 
The functional involvement of PFKFB3 S-glutathionylation in ROS regulation would 
also suggest a possible role of PFKFB3 in cell cycle progression in cancer cells. Recent studies 
have suggested that the abundance of PFKFB3 is tightly controlled during cell proliferation by 
ubiquitin ligases, APC/C-Cdh1 and SCF-β-TrCP (Almeida et al. 2010; Colombo et al. 2011). 
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Our study would provide an alternative explanation that PFKFB3 drives the cell cycle 
progression and, moreover, determines the timing of ubiquitination reaction of the ligases 
through ROS-dependent mechanisms rather than just being controlled during the cell cycle 
(Figure 3.5).  
 
 
Figure 3.5 Overview of the involvement of PFKFB3 S-glutathionylation in ROS regulation 
and in cell cycle progression in cancer cell. In the majority of tumors, upregulatedPFKFB3 
increases cellular ROS levels by activating glycolysis at the expense of the PPP.  An increase in 
ROS production promotes G1/S phase transition and inactivates two ubiquitin ligases, APC/C-
Cdh1 and SCF-β-TrCP. However, when the increases in ROS reach above a threshold for 
PFKFB3 S-glutathionylation after G1/S transition, the glutathionylated PFKFB3 triggers the PPP 
activation and subsequently ROS detoxification.  This decreased ROS levels attenuate ROS-
dependent inactivation of the ubiquitin ligases, leading to ubiquitination of PFKFB3 and its 
subsequent proteasomal degradation. 
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Up-regulated expression of PFKFB3 in the majority of tumors increases cellular ROS 
levels that trigger G1/S phase transition and inactivation of the two ubiquitin ligases, APC/C-
Cdh1 and SCF-β-TrCP40,41. When the increases in ROS reach above a threshold for PFKFB3 S-
glutathionylation after G1/S transition, the glutathionylated PFKFB3 lowers ROS levels. These 
decreased ROS levels attenuate ROS-dependent inactivation of the ubiquitin ligases, leading to 
ubiquitination of PFKFB3 and its subsequent proteasomal degradation (Almeida et al. 2010; 
Colombo et al. 2011). This potential involvement of PFKFB3 in cell cycle regulation can support 
the hypothesis of a link between and metabolic supply and cell cycle progression in cancer. 
Our results provide a new molecular understanding of how glucose metabolism and 
cellular ROS levels can be efficiently regulated by the S-glutathionylation of PFKFB3 in order to 
protect cancer cells against oxidative stress. The functional involvement of PFKFB3 S-
glutathionylation in ROS regulation would also suggest a possible role for PFKFB3 in cell cycle 
progression in cancer cells and a broader and more general role for ROS in the regulation of 
numerous biological processes, although further studies will be needed to elucidate the details of 
this mechanism. This new understanding will contribute to the development of appropriate 
therapeutic strategies for cancer prevention and treatment based on their redox profile. 
 
Materials and Methods 
Materials 
The following materials were obtained from the sources indicated. Dimethyl sulfoxide, 
oxidized L-glutathione, reduced L-glutathione, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) 
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(Sigma Chemical Co., St. Louis, MO, USA);Qdot 605 ITK streptavidin conjugate kit 2 µM 
solution, dextran alexafluor 488, anti-V5 antibody, calceinacetoxymethyl ester, PLUS Reagent, 
lipofectamine LTX Reagent (Invitrogen Corporation, Carlsbad, CA, USA);anti-glutathione 
monoclonal antibody (ViroGen Corporation); V5 antibody affinity purified agarose immobilized 
conjugate (Bethyl Laboratories); goat anti-mouse glutaredoxin-1/GLRX1 antibody (R&D 
Systems Inc.); glutaredoxin-1, glutaredoxin-1 antibody (Abcam). 
Plasmid Constructs and Mutagenesis 
  Full-length cDNA constructs for human PFKFB3 mutants, C206A, was generated by 
site-directed mutagenesis using the QuikChange II XL Site-Directed Mutagenesis Kit 
(Stratagene) following the manufacturer's recommendations and the commercially available 
vector pcDNA3.1/myc-HisA with human PFKFB3 as template. Briefly, mutant strand synthesis 
reaction was done by initial denaturation at 95°C for 1 min, followed by 18 thermal cycles at 
95°C for 50 s, 60°C for 50 s, and 68°C for 9 min 24 s, with a final extension at 68°C for 7 min. 
C206A-PFKFB3 was then subcloned from pcDNA3.1/myc-HisA into the pET3aM vector using 
NheI and BamHI restriction sites to create bacterial expression plasmids. All constructs were 
sequenced for verification. 
Protein Purification 
  The 6XHis-tagged human PFKFB1-4 and PFKFB3 mutants were expressed in 
Escherichia coli BL21(DE3) pLysS and purified using Ni-NTA affinity columns and, 
subsequently, Mono Q anion-exchange chromatography. 
Crystallization of S-Glutathionylated PFKFB3, Diffraction data collection and processing 
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The purified PFKFB3 was kept, after concentrating to 8 mg ml- 1 protein, in 20 mM 
Tris·HCl (pH 8.0), 10 mM NaPi, 5 mM β-mercaptoethanol, 5% glycerol. Crystals were prepared 
by the sitting-drop, vapor-diffusion method with a 1:1 (v/v) mixture of the protein sample with a 
reservoir solution of 50 mM MES pH 7 and 7% (w/v) polyethylene glycol 4000. Crystals with a 
size of 0.2 mm × 0.1 mm × 0.2 mm grew in two to three weeks. 
Crystals were soaked with a cryoprotectant solution containing different molar ratios of 
GSH/GSSG at constant total glutathione concentration of 10mM. A soaked crystal was flash-
frozen at 100 K using an Oxford cryo-device and kept at the same temperature during data 
collections. The diffraction data were collected at The Northeastern Collaborative Access Team 
(NE-CAT) Beamline at the Advanced Photon Source, Argonne National Laboratory, Argonne, 
IL. The X-ray source wavelength was 0.9792 A. The data recorded on a ADSC Q315 detector 
were integrated, merged, and scaled using XDS (Kabsch 2010). Statistics of the diffraction data 
and structure refinement are summarized in Table 3.1. The crystals belong to P6522 space group 
with similar cell dimensions. 
S-Glutathionylation of Purified PFKFB isoforms (SDS-PAGE and western blotting) 
To induce protein S-glutathionylation in vitro, purified PFKFB isoforms (0.3mg/ml) in a 
buffer containing 20 mM Tris-HCl (pH 8.0), 10 mM NaPi, 5% glycerol, 0.2 mM were incubated 
for 25min with 3mM of 1:1 molar ratios of GSH to GSSG (total concentration 3 mM) in 50mM 
Tris-HCl pH7.4 at room temperature. Samples were then mixed with Laemmli sample buffer 
without reducing agent or heating but with 1mM NEM for the alkylation of accessible thiols on 
PFKFB3, resolved in non-reducing SDS-PAGE, and transferred to nitrocellulose membranes. 
The Membranes were probed with anti-glutathione antibody (Virogen), followed by detection 
with horseradish peroxidase-conjugated secondary antibody (Novagen). Bands were visualized 
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by enhanced chemiluminescence (SuperSignal west pico, Pierce) according to the 
manufacturer’s instructions. Membranes were subsequently re-probed with anti-PFKFB3 
antibody (Abgent). 
Measurement of 2-Kase/2-Pase activity of PFKFB3 
The activity of 2-kase was performed as described previously(Seo et al. 2011). The 2-
Kase reactions were performed first and the Fru-2,6-P2 produced was measured by a 
conventional enzyme coupled assay. The reaction mixture contained 20 mM Tris–HCl (pH 8.5), 
0.5 mM MgCl2, 0.1mM ATP, and 10-20µg PFKFB3. The reaction was initiated by adding 
0.05mM Fru-6-P and incubation at 25 °C for 10 min, and the concentration of Fru-2,6-P2 was 
determined every 5 min. Fru-2,6-P2 was measured spectrophotometrically at 340 nm using the 
potato pyrophosphate-dependent 6-phosphofructokinase (PPi-PF1K) activation assay. 
To measure 2-Pase activity, a spectrophotometeric coupled enzyme assay was carried out using 
phosphoglucose isomerase and Glu-6-P dehydrogenase as described previously. The reaction 
mixture (total volume 200µl) contained 100 mM TrisHCl, pH 7.5, 0.2 mM EDTA, 100 µM 
NADP, 0.4 unit of Glu-6-P dehydrogenase, and 1 unit of phosphoglucose isomerase,. PFKFB3 
(0.2-0.4mg) was used in the 2-Pase activity assay. The reaction was initiated by the addition of 
100 µM Fru-2,6-P2 and all experiment were run at 25 °C. NADPH formation was measured at 
340nm using a microplate reader (Model 3550-UV, Bio- Rad). 
In Vitro (Synthetic) Enzymatic flux between glycolysis and the PPP (cell free) 
 To measure in vitro metabolic flux between glycolysis and the PPP upon PFKFB3 
glutathionylation, a spectrophotometeric coupled enzyme assay was carried out using PFKFB, 
phosphoglucose isomerase and Glu-6-P dehydrogenase. First, combined reactions of the first 
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step of the PPP and two steps in glycolysis between glucose-6-phosphate and fructose 1,6-
bisphosphate were initiated by the addition of 0.2mM Fru-6-P. Then, the formation of Fru-2,6-P2 
and NADPH was measured subsequently as representative products of each branch of our 
combining metabolic pathway.  The reaction mixture contained 50 mM gycylgycine (pH 7.5), 
0.5 mM MgCl2, 0.2mM ATP, 0.4 mM ß-nicotinamide adenine dinucleotide phosphate, 0.2-0.6 
unit of Glu-6-P dehydrogenase, 1 unit phosphoglucose isomerase, and 8-20µg PFKFB3. The 
reaction was initiated by adding 0.2mM Fru-6-P and incubation at 25 °C for 10 min and at every 
5 minutes, aliquots were transferred into 125 mM NaOH. The NADPH formation was directly 
measured at 340nm and Fru-2,6-P2 produced was measured by a conventional enzyme coupled 
assay system. 
 
Cell culture, transient transfection and oxidant treatments 
293T and HeLa cells were obtained from ATCC and cultured in DMEM containing 2mM 
glutamine, 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin (all 
from GIBCO-BRL). All cells were cultured in a humidified incubator at 37 °C/5% CO2. Cells 
expressing specific PFKFB3 mutants were established by transfecting cells with 
pcDNA3.1/myc-HisA-PFKFB3 WT and mutant(s) using GeneJuice® transfection reagent 
(Novagen). Overexpression of PFKFB3 was confirmed by Immunoblotting analysis. BCNU 
[N,N'-bis(2-chloroethyl)-N-nitro-sourea] and H2O2 (hydrogen peroxide) were from Sigma and 
used as described in the text. 
Detection of Glutathionylation of PFKFB3 in 293T and HeLa cells 
 293T and HeLa cells expressing PFKFB3 were loaded with 1mM biotinylated 
glutathione ethyl ester (BioGEE, Invitrogen) and incubated for 1 h followed by an H2O2 
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treatment for 15 min or BCNU treatment for 3 h.  The cells were lysed in a modified RIPA 
buffer (0.01 M sodium phosphate (pH 7.2), 150 mM NaCl, 0.1mM EDTA, 1% Nonidet P-40, 1% 
sodium deoxycholate, and 0.1% SDS, 10 mM N-ethylmaleimide) supplemented with a protease 
inhibitor mixture (Roche). Glutathionylated PFKFB3 levels were measured after pull down with 
streptavidin-dynabeads (Invitrogen) according t according to the manufacturer’s protocol 
followed by reducing SDS-PAGE and Western blot analysis with anti-PFKFB3 antibody. 
 For detection of endogenous PFKFB3 glutathionylation, cells were treated with 10µM 
proteasome inhibitor MG132 for 8 h before BioGEE incubation. Then cells were prepared as 
described above. 
Metabolite determination 
HeLa cells were plated at a density of 1x107 in T 175 culture flasks in DMEM containing 
10% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells expressing 
specific PFKFB3 mutant were established by transient transfection the following day.  After 
36hours of incubation, the media were replaced with fresh DMEM containing either H2O2, 
BCNU or GSHee at the indicated concentrations and time. Media samples were collected for 
measuring the lactate secretion levels using a lactate oxidase-based assay kit (Sigma-Aldrich).   
The cells were washed, scraped, and collected. Extract cells with Lysis buffer containg0.01 M 
sodium phosphate (pH 7.5), 150 mM NaCl, 5mM EDTA, 1% Nonidet P-40 and 5% 5-
sulfosalicylic acid (SSA). Before each assay add ice cold 2M KOH to SSA preserved sample to 
neutralize the samples. The Fru-2,6-P2 level was determined with collected cells after the 
treatment, using the method described previously (Seo et al. 2011) 
 For the quantification of the PPP flux, levels of Ribul-5P and Xyl-5P were monitored. First, The 
quantification of mixture of Ribul-5P, Xyl-5P, and glyceraldehydes-3-phosphate (G-3P) was 
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performed in a system containing 58 mM glycylglycine, 3.3 mM xylulose 5-phosphate, 0.002% 
(w/v) cocarboxylase, 15 mM magnesium chloride, 0.14 mM ß-nicotinamide adenine dinucleotide, 
reduced form, 15 mM magnesium chloride , 20 units a-glycerophosphate dehydrogenase, 5 units 
triosephosphate isomerase, 0.1 unit ribulose 5-phosphate 3-epimerase, and 5 units transketolase 
as described previously (Boada et al. 2000). Then, levels of G-3P have been measured under 
same condition except adding ribulose 5-phosphate 3-epimerase and transketolase and subtracted 
from the levels of mixture Ribul-5P, Xyl-5P, and G-3P. Protein concentration was measured 
using QuantiPro BCA assay kit (Sigma-Aldrich) and metabolite concentrations were normalized 
to the total cellular protein concentration. 
ADP/ADPH, GSH/GSSG and ROS measurements 
Cells were prepared as described above in Metabolite determination. Cellular 
GSH/GSSG and NADP/NADPH levels were analyzed spectrophotometrically by using a 
GSH/GSSG measurement kit or NADPH assay kit (Abcam) according to the manufacturer's 
instructions.  
For ROS measurements, the medium was aspirated, pre-treated cells were washed 1x with PBS, 
harvested by trypsinization and processed for flow cytometry. Cells were subsequently incubated 
with HBSS containing and 10 µM chloromethyl-H2DCFDA (CM-H2DCFDA, Invitrogen) in 
DMSO for 30min at 37oC, while still maintaining the H2O2 or BCNU treatment. The 
fluorescence of samples were analyzed by flow cytometry (FACSCalibur®, Becton Dickinson 
Immunocytometry) using the CellQuest (BD Bioscience) software. 
Cell Viability assay 
Cell viability experiments were determined by trypan blue staining. Cells were plated at a 
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density of 3.5X104per well in a 24-well plate in DMEM containing 10% FCS. Cells expressing 
PFKFB3 mutant were established by transient transfection the following day.  After 20hours of 
incubation, the media were replaced with fresh DMEM containing H2O2, BCNU or GSHee at 
the indicated concentrations. After 30 hours of incubation with vehicle or compounds, cells were 
trypsinized and cell viability was determined by the trypan blue exclusion assay using a 
hemacytometer.  
Structure determination and refinement 
The reduced data were formatted for the program suites of CCP4 (1994)and 10% of the 
data were marked for free R-factor measurements in subsequent structure refinements. The 
search model was built from the coordinates of the PFKFB3•Fru-6-P•EDTA complex structure 
(PDB accession code 2AXN) (Kim et al. 2007) by stripping all the included ligand and solvent 
molecules to determine the complex structures of glutathionylated PFKFB3. The initial model 
was determined using REFMAC within the CCP4 suit and processed through iterated cycles of 
manual model rebuilding and validation using the program COOT(1994). Binding of the ligands 
was confirmed, referring to the |Fo|–|Fc| omit maps that were generated, when Rcrys/Rfree 
reached 0.23/0.29 or below. Referring to these maps, GSH was incorporated into the 
corresponding complex models.  As summarized in Table 3.1, the final model of the 
glutathionylated PFKFB3 has Rcrys/Rfree of 0.209/0.257 using a total of 3939 scatterers, 
including solvent molecules, against all available 37,905 reflections in the resolution range of 
47.7–2.2 Å.  The structure contains a total of 443 amino acid residues of the full-length protein 
of 520 residues. As in the PFKFB3•ADP•EDTA complex, the C terminus (residues 461–520) is 
mostly disordered. 
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Table 3.1 Statistics of reflection data and structure refinements 
 PFKFB3·SSG 
Space group P6522 
Unit cell dimensions   
a = b (Å) 102.50 
c (Å) 260.61 
Resolution range (Å) 47.7-2.2 
No. reflections used  37,905 
Completeness (%) 99.7 
Redundancy 3.6 (3.6) 
I/σ (I) 7.9 
Rsym 0.081 
Rcrys 0.209 
Rfree 0.257 
No. amino acids 457 
No. protein atoms 3676 
No. hetero atoms 109 
No. water molecules 160 
r.m.s.d. from ideal   
Bond lengths (Å) 0.024 
Bond angles (deg.) 2.22 
Dihedral angles (deg.) 20.5 
Mean Bfactor   
Protein atoms (Å2) 33.6 
Hetero atoms (Å2)  47.5 
Water atoms (Å2) 36.3 
Rsym = ∑h(∑j|Ih,j–<Ih>|/∑Ih,j), where h = set of Miller indices, j = set of observations of 
reflection h, and <Ih>=the mean intensity. Rcrys= ∑h||Fo,h|–|Fc,h||/∑h|Fo,h|. Rfree was 
calculated using 10% of the complete data set excluded from refinement. The numbers in 
parentheses represent values from the highest resolution shell. 
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CHAPTER 4: COCLUSIOS 
Alterations to cellular metabolism are a hall mark characteristic of cancer cells and 
ubiquitous to almost every types of cancer. In fact, these metabolic alterations seem to be 
required for cancer cells in order to enhance their growth and malignant transformation. The 
metabolic alterations of cancer cells often display enhanced energy production, increased 
macromolecular synthesis, and maintenance of proper redox homeostasis. A deeper 
understanding of the unique properties of cancer cells will provide promising strategies for 
cancer drug development. The reliance on glycolysis for energy production, one of the metabolic 
perturbations in cancer cells, is strongly linked to a high kinase activity of PFKFB3, which is 
solely responsible for the cellular concentrations of an activator of glycolysis, F-2,6-P2.  As this 
metabolic conversion has been suggested to be a hallmark of cancer, PFKFB3 has emerged as a 
novel target for cancer chemotherapy. In this study, we report that a small molecular inhibitor, 
N4A, was identified as an initial lead compound which almost constantly inhibits PFKFB3 with 
therapeutic potential. Understanding the interaction between a potential drug molecule and its 
target protein at the molecular level is of central importance to successful drug development, 
allowing an opportunity of structure-guided optimization. In attempt to improve its potency, we 
determined the crystal structure of the PFKFB3•N4A complex to 2.4 Å resolution and attained 
the more potent YN1 by exploiting the resulting molecular information. When tested on cultured 
cancer cells, both N4A and YN1 inhibited PFKFB3, suppressing the F-2,6-P2 level, which in turn 
suppressed glycolysis and, ultimately, led to cell death.  This study validates PFKFB3 as a target 
for new cancer therapies and provides a framework for future development efforts.    
We also found that PFKFB3 plays an important role in the maintenance of the optimal 
redox balance, one of the three crucial requirements of the metabolic adaptations in cancer cells.  
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In addition to its known harmful effect, recent evidence suggests that ROS also functions as 
intracellular messengers to modulate the activities of various proteins in the signaling pathways 
that are involved in stress response and cell survival. Moderate levels of reactive oxygen species 
(ROS) can support cell proliferation, whereas excessive levels of ROS cause detrimental 
oxidative stress that damage cellular components and lead to cell death.  Cancer cells exhibit 
higher levels of ROS, compared to their counterparts, normal cells, because tumorigenic 
conditions, including aberrant metabolism, hypoxia, inflammation and mitochondrial 
dysfunction, constantly generate ROS.  Therefore, cancer cells are challenged in regulating ROS 
not only to avoid the toxic effects of excessive ROS, but also to promote metabolic alterations in 
cancer, high energy production and macromolecule synthesis, thereby supporting ROS-induced 
proliferation and oncogenic mutations. However, the molecular mechanisms underlying redox 
adaptation and ROS regulation in cancer cells have remained poorly understood.   It is necessary 
to understand the complex redox alterations in cancer cells and the underlying mechanisms for a 
promising strategy in cancer treatment. We show that PFKFB3 undergoes isoform-specific S-
glutathionylation under excessive oxidative stress.  S-glutathionylation of PFKFB3 leads to 
inactivation of the kinase activity, a consequential decrease in the levels of Fru-2,6-P2, ultimately 
resulting in glycolysis inhibition and the PPP stimulation. This redirection of glucose 
consumption at the high ROS levels enhances NADPH generation for ROS detoxification to 
down-regulate oxidative stress. Low ROS levels reverse S-glutathionylation to recover the 
PFKFB3 activity, leading to enhanced rates of glycolysis with increased ROS production to 
promote proliferation and additional oncogenic mutagenesis. This strongly indicates that 
PFKFB3 acts as a metabolic master switch that senses and controls cellular redox status.  By 
regulating both metabolic pathways, glycolysis and the PPP, S-glutathionylation of PFKFB3 
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plays an essential role in maintaining moderate ROS levels below a toxic threshold and within a 
range that can support tumor progression.  
  Together, this study indicates the importance of PFKFB3 function in metabolic 
alterations and adaptations of cancers and thus will have an immediate impact on development of 
anti-cancer therapeutics and strategies of chemotherapy. Our finding also suggests possible 
therapeutic implication of drug cocktail of PFKFB3 inhibitors in combination with the 
conventional drugs, providing more effective cures in combating cancer. 
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